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LIST OF ABBREVIATIONS 
 
IHA    - Immune Hemolytic Anemia 
AIHA   - Autoimmune Hemolytic Anemia 
WAIHA - Warm Autoimmune Hemolytic Anemia 
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DTT   - di-thiotheritol 
2-ME  - 2-Mercaptoethanol 
ET    - Exchange Transfusion 
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INTRODUCTION 
The direct antiglobulin test (DAT) is used to determine whether the red 
blood cells are coated in vivo with antibodies such as immunoglobulin, complement 
or both. The direct antiglobulin test is also referred as the Direct Coombs’ test since 
it is based on the test developed by Coombs, Mourant and Race.
1  
   Depending on the technique and the reagents used, a positive direct 
antiglobulin test has been reported in 1:1000 to 1:14,000 blood donors and 1% to 
15% of hospital patients.
 
The direct antiglobulin test is used most commonly to 
investigate possible haemolytic transfusion reactions, haemolytic disease of the fetus 
and newborn (HDFN), autoimmune haemolytic anaemia (primary or secondary), 
alloimmune haemolytic anaemia and drug induced immune haemolysis.
2
 These 
coated red cells are difficult to cross match, which is required for selection of an 
appropriate unit of blood for transfusion in this patients.
3 
Clinical picture of WAIHA is highly variable. Most patients have symptoms 
correlated to anaemia, such as fatigue, palpitations and shortness of breath. 
Occasionally massive haemolysis manifested by haemoglobinuria, haemglobinemia 
and profound anaemia can be seen with secondary WAIHA.
4
  
Direct antiglobulin test (DAT) is used to determine whether the red cells 
have been coated in vivo with IgG or complement or both. Stronger the DAT, the 
antibody is expected to cause more haemolysis if the antigen positive donor unit is 
transfused.
5 
The DAT can be initially performed with a polyspecific antihuman 
globulin (AHG) reagent that is capable of detecting both IgG and C3d. If the results 
are positive, tests with monospecific reagents (anti-IgG and anti-complement) need 
to be performed to appropriately characterize the immune process involved and 
determine the diagnosis.
6 
Then removal of antibodies from in vivo sensitized red 
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cells by elution technique to identify them. Various elution procedures are used for 
dissociating antibodies from red cells. In studies Elution removes antibody 
molecules from the red cell membrane either by disrupting the antigen or changing 
conditions to favour dissociation of antibody from antigen conducted for the 
efficacy of various elution methods viz., Acid elution, Glycine-HCl/EDTA, heat 
elution and Chloroquine diphosphate, and Cold elution, the Acid elution method is 
suitable for eluting auto and allo Antibodies present on the RBCs .
7 
Clinical signs and symptoms of immune haemolysis are present. Serum test 
results are negative or inconclusive for a patient who has been recently transfused. 
HDFN is suspected but no alloantibodies were detected in the maternal plasma.
8 
 Usually the same specificity can be detected in the patient’s (or, in HDN, the 
mother’s) serum, eluate is of increased help in antibody identification when serum 
reactions are weak. When the eluate reacts with all cells tested, autoantibody is the 
most likely explanation, especially if the patient has not been recently transfused. 
When no unexpected antibodies are present in the serum, and if the patient has not 
been recently transfused, no further serologic testing of an isolated autoantibody is 
necessary. Sometimes no reactivity is detected in the eluate, despite reactivity of the 
cells with specific anti-IgG. The cause may be that the eluate was not tested against 
cells positive for the corresponding antigen, notably group A or group B cells.
9
 
 
This cross sectional study is conducted to find out serological 
characterization of red cell bound antibodies with regard to antibody class, subclass, 
DAT strength and their correlation with in vivo haemolysis and also the effect of 
acid elution (glycine acid /Glycine acid EDTA) in DAT positive patients. 
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AIM AND OBJECTIVES 
AIM 
 To determine class and subclass of red cell bound antibodies in Direct 
Antiglobulin Test positive cases and to perform elution studies to find out antibody 
specificity. 
OBJECTIVE 
1. To find the class and subclass of red cell bound antibodies thereby 
appropriately characterizing the immune process involved and determining 
the diagnosis. 
2. To study the correlation between Direct Antiglobulin Test strength and in 
vivo haemolysis based on clinical parameters. 
3. To perform elution studies in Direct Antiglobulin Test (IgG) positive cases 
and to determine antibody specificity. 
4. To distinguish between auto antibody and alloantibody. 
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REVIEW OF LITERATURE 
 
THE DIRECT ANTIGLOBULIN test (DAT) is a simple test used to 
determine if the red cells have been coated in vivo with immunoglobulin (Ig), 
complement, or both. The DAT is used primarily for the investigation of 
autoimmune hemolytic anemia (AIHA), drug-induced immune hemolysis, hemolytic 
disease of the fetus and new-born (HDFN) and hemolytic transfusion reactions,. A 
positive DAT result may or may not be associated with immune mediated 
hemolysis.
3
 
HISTORY OF DAT 
“The first lesson to be learned in history is that the path of process is 
anything but straight.” 
In the 1940s, the actual nature of antibodies was still unknown, but seemed 
to be associated with the serum globulins. Race, Mourant and Weiner concluded that 
there were two types of Rh antibody: one that bound to the RBC surface and caused 
agglutination (the “complete” antibody) and another that absorbed to the RBC 
surface but did not cause agglutination (the “incomplete” antibody).1 
In 1945, Coombs, Mourant and Race described technique for detecting 
attachment of Rh antibodies in serum that did not produce agglutination. This test is 
known as the antiglobulin test (AHG) and uses antibody to human globulin. In 1946, 
Coombs and associates described the use of AHG to detect in vivo sensitization of 
the red cells of babies suffering from hemolytic disease of the new-born (HDN). 
Although the test was initially of great discovery in the investigation of Rh 
hemolytic disease of the new-born, it was not long before its use for detection of 
other IgG blood group antibodies became clearly evident. The first of the Kell blood 
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group system antibodies and its associated antigen were reported only weeks after 
Coombs had described the test.
1,2 
The principle of the instrumental in introducing the antiglobulin test to blood 
group serology had in fact been described by Moreschi in 1908 before Coombs and 
associates. The study of Moreschi involved the use of rabbit anti-goat serum to 
agglutinate rabbit red cells, which were sensitized with low no agglutinating does of 
goat anti-rabbit red cells serum. Coombs’s production involved the injection rabbits 
with human serum to produce antihuman serum. The absorption is used to remove 
heterospecific antibodies and the dilution to avoid prozone but the antiglobulin 
serum still retained sufficient antibody activity to permit cross-linking of adjacent 
red cells coated with IgG antibodies.
1 
The antiglobulin test was first used to demonstrate antibody in serum, but 
later the same principle was used to demonstrate in-vivo sensitization of red cells 
with antibodies or complement components. As used in immunohematology, 
antiglobulin testing generates visible agglutination of sensitized red cells. An 
indirect antiglobulin test is used to demonstrate in-vitro reactions between red cells 
and antibodies that sensitize, but do not agglutinate, cells that express the 
corresponding antigen.
11 
STRUCTURE OF IMMUNOGLOBULINS 
 Immunoglobulin (Ig), is a complex protein produced by plasma cells, with 
specificity towards specific antigens. Each specific antigen stimulates the production 
of specific antibody. These antibodies, binds to the antigen, and/or fixes 
complement, facilitate phagocytosis, and neutralises toxic substances found in the 
circulation. Thus, antibodies have various functions, some type of Immunoglobulins 
are highly specialized and more specific than others.  
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Immunoglobulins are also called as antibodies; they are made up of four 
polypeptide chains-two identical heavy chains (H) and two identical light chains (L). 
Light chains have molecular weight of approximately 22,500 Daltons and heavy 
chains have molecular weight of 50,000-75,000 Daltons which are interconnected by 
covalent disulfide bonds. The heavy chains are held together by disulfide bonds at 
their hinge region. The H chains differ in structural and antigenic properties. These 
chains determine the class and subclass of the molecule. 
Five different classes of Ig are recognized, IgG, IgM, IgA, IgD and IgE, and 
these have different H chains, termed gamma (γ), mu (μ), alpha (α), delta (δ) and 
epsilon (ε). Igs of all five classes have the same L chains, although these may be 
either kappa (κ) or lambda (λ). In each Immunoglobulin molecule, the two L chains 
are the same, e.g. a molecule may be γγκκ or γγλλ, it is the variation in the heavy 
chains makes difference in each type of immunoglobulins. IgG is the most common 
and concentrated in serum, consisting nearly 80% of the total serum 
immunoglobulin; second most common immunoglobulin is IgA, present as 13% of 
total immunoglobulins predominantly found in body secretions. IgM has a 
concentration of 6%; IgD is 1% and IgE is the least common immunoglobulin 
present less than 1%.
5 
IgG molecules occur as monomers, IgM molecules as 
pentamers, e.g. (μ2λ2)5, and IgA molecules as monomers or dimers.  
Immunoglobulins are protein molecules have two terminal regions, these are 
the amino (NH2) terminal and the carboxy (COOH) terminal. Amino terminal 
region consisting both light and heavy chains of immunoglobulin is known as the 
variable region. This variation in the structure is according to the great variation in 
antibody specificity and it is responsible for antigen binding. The carboxy terminal 
of all heavy chains has a constant aminoacid sequence and is named as constant 
region. The Fc region extends from the carboxy terminal to the hinge region and is 
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primarily responsible for monocyte binding and complement fixation on Fc 
receptors present on the cell. The Fab fragments extend from the amino terminal to 
the hinge region of the molecule. 
  In Immunoglobulin molecule the domains are made up of regions of both 
heavy and light chains, folded into globular structures or loops and these are made 
up of approximately 110-120 amino acids. The domains consist of variable (V) and 
constant (C) regions which are made up heavy and light chains. The number of 
domains depends upon the immunoglobulin isotype. Three constant heavy chain 
regions (CH1, CH2, CH3) domains are noted IgG, IgA, IgD and four constant 
domains CH1 to CH4 noted on the heavy chains of IgE and IgM. Particular 
biological properties of immunoglobulins IgG and IgM are especially associated 
with certain heavy chain domains and complement fixation. The hinge region of 
immunoglobulin structure exists between the CH1 and CH2 domains of the heavy 
chain. Minor differences in the hinge regions are used to subtype IgG into four 
subclasses. In IgG molecules there is a specific constant heavy region (CH2 and 
CH3) which allow for attachment of Fc receptors of monocytes and macrophages. 
IgM is a pentamer with a molecular weight of approximately 900 kDa and 
consists of five subunits with weight of 180kDa each. Each subunit is linked by J 
chain, which is a sulfhydryl-rich peptide (15 kDa) and it consists of two heavy 
chains µ and two light chains of type κ or λ. J chain contribute to integrity and 
stability of the pentameric structure of IgM. The Fc fragment of IgM is a cyclic 
pentamer with molecular weight of approximately 340 kDa.  
There are two forms of IgA. One is a monomer and other exists in a 
polymeric form- as dimers or trimers composed of two or three identical monomers 
respectively and are joined by a J chain. IgA is located in different parts of the 
immune system depending upon the subclass. In serum IgA is found in both 
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monomeric and polymeric forms. Secretary IgA is normally found in mucosal 
tissues of the body. The polymeric form of secretary IgA acquires a glycoprotein 
secretary component and when it passes through epithelial cell walls of mucosal 
tissues and this appears in nearly all body fluids. Another importance of the IgA is 
that it can increase the effect of IgG induced RBC hemolysis.
13
  
 In Sudipta Sekar Das et al study, Multiple red cell bound antibodies had 
(83.3%) severe in vivo hemolysis compared to only (22.6%) single autoantibody.
14 
SUBTYPE OF IgG AND HEMOLYSIS 
IgG antibodies is subdivided into four subclasses on the basis of minor 
structural differences in the hinge region of the IgG structure. The IgG subtypes are 
IgG1, IgG2, IgG3 and IgG4. The ratio of κ to λ in human IgG is 2:1, but the ratio is 
1:1 and 1:8 for individuals with IgG2 and IgG4 subclasses respectively. The 
disulfide bonds linking the heavy chains also act as a factor for structural variations 
among the different subclasses. While IgG1 and IgG4 have two bonds each, IgG2 
and IgG3 have four and five bonds respectively. This disulfide bond is responsible 
for flexibility to the hinge region of the subclasses of IgG molecule and the distance 
or angle of Fab fragments determines the antigen it can accommodate.
15 
Each of the subclasses exhibit differences in properties including placental 
transfer and complement fixation. While IgG1 and IgG3 binds to complement C1q 
molecule more strongly than IgG2. IgG4 doesn’t bind at all and cannot activate 
complement cascade.
16
 In case of IgG2, there are two alleles of the particular gene 
that encodes the FcRIIa receptors on macrophages. As a result some people have 
low affinity receptor for IgG2 and these subjects show positive DAT in the presence 
of IgG2 autoantibody without the signs of hemolysis. Subjects with high affinity 
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receptors have the potential to destroy IgG2 coated cells. However IgG2 mediated 
hemolysis also depends upon the antigen specificity. 
Macrophages have IgG Fc receptors only for IgG1 and IgG3
17, 18
 therefore; 
the quantity and type of IgG on the red cell surface influence the degree of 
hemolysis. Studies done on IgG subtypes revealed that red cells coated with IgG1 
alone or in combination with IgG2 or IgG4 require an average of 2000 molecules of 
IgG per red cell to stimulate phagocytosis and rosette formation in vitro. However in 
case of IgG3 subtype, an average of 230 IgG3 molecules per red cell is required for 
monocyte binding.
19
 Only IgG1 and IgG3 are efficient in activating complement. 
Destruction of red cells is further enhanced when complement is also present on the 
red cell membrane. 
Since two molecules of IgG in close proximity is required to bind C1q and 
activate complement system,
20
 there must be a sufficient number of antibody 
molecules and antigenic sites for complement attachment. Once C1 is bound, C4 and 
C2 activated to form C3 convertase, which then cleaves C3 and C3b. Several 
hundred molecules of C3b bound to the red cell membrane through the action of a 
single C3 convertase enzyme complex.
21 
The IgG Fc and complement receptors act together to enhance the binding of 
red cells coated with IgG and complement. Removal of IgG-coated red cells with or 
without complement occurs primarily in the spleen. However, spleen plays dominant 
role in destruction of IgG coated red cells. As there is no C3 or iC3b in normal 
plasma, there is no competition for the macrophage complement (CR1 and CR3) 
receptors in the liver; thus the splenic macrophages have no more efficiency than 
Kupffer cells in destruction of C3-coated RBCs. C3b does not remain on the red cell 
very long. If the C3b-coated red cell does not interact, or if the interaction with a 
C3b receptor on a macrophage is inefﬁcient, the cell-bound C3b is denatured. 
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Naturally occurring complement control enzymes factors H and I cleave C3b 
molecules, ﬁrst forming iC3b, then a second cleavage breaks away C3c, leaving 
only C3dg on the RBC membrane. C3dg can be further cleaved in vitro, using 
trypsin, to C3d.
18
 The spleen acts as a fine filter and the liver acts as a coarse filter of 
sensitized red cells in immune hemolytic anemias (IHA).
 
Of the subclasses of IgG, IgG3 has the highest affinity for the FcγR and 
therefore most efficient causing extravascular hemolysis (IgG3˃ IgG1˃ IgG2˃˃˃ 
IgG4).
22, 23 
The most prominent subclass of warm autoantibody found in most warm 
AIHA patients is IgG1.
26 
IgG3 antibody is mostly found in combination with other 
subclasses in 5% of patients and found as a solitary antibody in 3% of patients.
28
 R.J 
Sokol et al., in their study found that IgG3 is rarely found as a single class and it is 
found alone in 1% in their study population.
13 
J. Fabijan´ska-Mitek H. Lopien´ska B. Zupan´ska The IgG subclasses were 
detected by the gel test in 100% of the AIHA cases. In 95.5% of the patients IgG1 
was detected, either alone (59.1%) or together with other subclasses (36.4%). 
Multiple IgG subclasses were also associated with more pronounced haemolysis: 
severe haemolysis in 61% of the cases, moderate in 33%, most of them with IgG3. 
In most of the cases with mild haemolysis, only IgG1 was detected (69%); if other 
subclasses were found, they were IgG2 or IgG4, but never IgG3.
29
  
In Sudipta Sekar Das et al study,. IgG1 alone or in combination with IgG3 
were the predominant IgG subclasses. In 46.5% of the patients the subclass was 
IgG1 or IgG3 or both.
14
  
Janet M. Pollock, John M. Bowman distribution of anti-D subclasses in 
HDFN was 3% IgG3 alone, 33% IgGl alone, and 64% IgGl and IgG3.
30
 Frankowska 
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and Gorska found that 87.6% pregnant women contained IgG1 Rh antibodies, 23% 
contained IgG2 antibodies, 56.9% contained IgG3 antibodies, and 7.7% contained 
IgG4 antibodies. Most commonly, the sera contained IgG1 alone (33.9%) or IgG1 + 
IgG3 (32.3%); no sera contained IgG2 and/or IgG4 without IgG1 or IgG3.
31
  
In the study conducted by Schanfield, neonates born with RBCs sensitized 
with IgG1 Rh antibodies had lower mean cord hemoglobin and higher cord bilirubin 
levels, with a lower postnatal bilirubin rise, than neonates with IgG3-sensitized 
RBCs. He suggested that this finding related to the preferential placental transfer of 
IgG1, which allowed for a longer period of in utero IgG1 sensitization. In contrast, 
neonates with IgG3 sensitization tended to have higher mean cord hemoglobin and 
lower cord bilirubin levels, but a higher postnatal rise in bilirubin. This was thought 
to be due to the shorter in utero exposure to IgG3 but the relative higher efficiency 
of IgG3 in causing postnatal RBC destruction.
32 
Sanford et al., Patients with acute hemolytic transfusion reactions or delayed 
hemolytic transfusion reactions (DHTRs) may have a positive direct antiglobulin 
test (DAT) result with immunoglobulin (Ig)G and/or complement fixation  
(eg, C3d).
33 
IMMUNOGLOBULINS AND COMPLEMENT ACTIVATION 
The complement system is a complex group of more than 20 circulating and 
cell membrane proteins with various functions within the immune response. Primary 
roles include direct lysis or destruction of cells, bacteria and enveloped viruses as 
well as helping with opsonisation to facilitate phagocytosis. 
The complement proteins are activated by cascade of events mainly through three 
pathways: 
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1. Classical 
2. Alternative and 
3. Lectin pathways. 
The three pathways converge at the activation of the component C3. The 
classical pathway is activated by the binding of an antigen with IgM, IgG1 or IgG3 
antibodies. The activation of classical complement pathway is initiated when an 
antibody binds to antigen. This allows the binding of the complement protein C1 to 
Fc fragment of IgM, IgG1 or IgG3 antibody. Ability of IgG antibody for 
complement activation depends on cell surface antigenic concentration and antigen 
clustering, in addition to antibody avidity and concentration. IgM is large and has Fc 
monomers close to each other on one immunoglobulin molecule; therefore only one 
IgM molecule is sufficient to activate complement. 
The C1 component is a complex composed of three C1 subunits C1q, C1r 
and C1s which are stabilized by calcium. In the C1 complex, C1q is responsible for 
catalysing C1r to generate activated C1s. activated C1s is a serine-type protease. The 
C1qrs complex acts on C2 and C4 to form C4b2a. C4b2a uses component C3 as a 
natural substrate and C3b which is formed attaches to microbial surface. Some C3b 
attaches to C4b2a complex and resulting C4b2a3b complex functions as C5 
convertase. The C5 convertase acts on C5 to produce C5a (a strong stimulator of 
anaphylotoxins) and C5b, which binds to the cell membrane and helps C6, C7, C8 
and C9 complements to the cell membrane. When C5b along with C6, C7, C8 and 
C9 are bound membrane attack complex is formed; this causes cell lysis.  
In patients with cold agglutinin disease, serum levels of complement proteins 
C3 and C4 are low in most patients because of constant consumption, which may 
limit further extra and intra vascular hemolysis.
34 
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Salama and Mueller-Eckhardt observed that the patients with DHTRs found 
to have IgG and C3d detectable on their RBCs after the reaction.
35
 Ness and 
coworkers detected RBC-bound IgG by the DAT in all (100%) patients; however, 
56% of them also had RBC-bound complement.
36 
CAUSES OF POSITIVE DAT 
Patients with Clinical and/or laboratory evidence of hemolysis and DAT 
positivity are broadly classified into Immune hemolytic anemia (IHA). Further, they 
are classified into AIHA, DiAIHA and Alloimmune Hemolytic Anemia 
(Transfusion reaction and HDFN).
24
  
Autoimmune Hemolytic Anemia 
The Classification of AIHA is patho-physiologically based and divides 
AIHA into warm, mixed or cold-reactive subtypes. This thermal-based classification 
is based on the optimal autoantibody-RBC reactivity temperatures. AIHA is further 
subcategorized into idiopathic and secondary with the secondary AIHA being 
associated with a number of underlying infectious, neoplastic and autoimmune 
disorders. {Uncompensated autoantibody-mediated red blood cell (RBC) 
consumption is the hallmark of autoimmune hemolytic anemia (AIHA)}.
2, 13, 37, 38 
Further sub-classification of cold AIHA (cAIHA) includes primary and 
secondary cold agglutinin syndrome (CAS) and paroxysmal cold AIHA.
37-39
 While 
warm AIHA and cold AIHA constitute much of the AIHA prevalence some less 
frequent types do arise, namely mixed-type AIHA (mAIHA) and drug-induced 
AIHA (diAIHA). In most cases AIHA is confirmed by a positive direct antiglobulin 
test (DAT). diAIHA is even more rare, afflicting an estimated 1 in 1 million. 
diAIHA can be classified into sub-categories depending on if the drug is required to 
be present for hemolytic activity (drug-dependent AIHA), or if hemolytic activity is 
14 
 
observed without the drug present (drug-independent AIHA).
40
 While each subtype 
of AIHA is innately part of the same family, pathogenesis, diagnostics, treatments, 
and prognosis vary greatly. Accurate diagnosis is therefore crucial to assess clinical 
manifestations, predisposing factors and treatment optimization. 
Warm autoimmune hemolytic anemia (WAIHA) 
 An estimated 1 in 80,000 are afflicted by WAIHA, constituting about 
75% of all AIHA cases.
40
 Idiopathic/Primary AIHA accounts for approximately half 
of all WAIHA.
40
 Warm AIHA is the subtype that most often affects children age 
between 2–12 years.42Secondary WAIHA is associated with various conditions 
including infectious mononucleosis, systematic lupus erythematosus (SLE), 
autoimmune hepatitis, human immunodeficiency virus, and other 
lymphoproliferative or autoimmune disorders.
13, 35, 39, 43 
Of AIHA-associated 
lymphoproliferative disorders chronic lymphocytic lymphoma (CLL) is the most 
common cause.
44
 In fact, roughly 11% of CLL patients develop secondary WAIHA, 
while an annual incidence of 2–3% is observed in patients with non-Hodgkin's and 
Hodgkin's lymphoma.
42-44
 The polyclonal immunoglobulin (Ig) class IgG is 
typically involved in the autoantibody activity of warm AIHA (WAIHA), showing 
maximal reactivity with erythrocytes at 37 °C. Less frequently, WAIHA can be 
associated with IgA and IgM. WAIHA exhibits a depleted immune tolerance of 
RBCs commonly due to the binding of self-antibodies to Rh proteins, causing Fc-
gamma receptors to mediate removal of RBCs extravascularly within the spleen.
37
 
WAIHA has recently been linked to a number of immune system imbalances. 
Interleukin-12 (IL-12) and interleukin-10 (IL-10) imbalances are believed to 
mediate the altered immune response in some patients with AIHA.
44,47
 The pattern 
of IL-10 and IL-12 production is generally thought to play a role in the pathogenesis 
of WAIHA and correlates with increased activity of the Type-2 Helper T Cell (Th2) 
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pathway and the inhibition of Type-1 Helper T Cell (Th1) pathway.
46,47
 The 
domination of the Th2 pathway leads to increased autoantibody production 
mediating AIHA.
46-50 
Most observers have reported a somewhat higher incidence in females than 
in males. In idiopathic cases of WAIHA, Allgood and Chaplin reported that 60% of 
patients were female;
51
 Dausset and Colombani reported that 61% of patients were 
female;
52
 Pirofsky indicates that 64% of patients were female;
 41
 Dacie reported 58% 
of patients were female;
 39
 Dacie and Worlledge reported that 59% of patients were 
female;
53
 and, in the series reported by Böttiger and Westerholm, women 
predominated in all age groups with the exception of the youngest (0 to 14 years), in 
which the sex distribution was even.
54
 In secondary WAIHA, the percentages are 
more varied, perhaps depending on the incidence of underlying diseases seen in 
referral centers. 
Cold autoimmune hemolytic anemia (cAIHA) 
Cold agglutinin syndrome (CAS) 
CAS is much less prevalent than WAIHA, comprising about 15% of all 
AIHA cases, primarily occurring in the middle aged or elderly. CAS causes AIHA 
in a complement-dependent manner where autoantibody-dependent lysis is mediated 
primarily by C3 proteins, leading to intravascular hemolysis upon detachment of 
antibodies at 37°C.
55
 Targeted RBC phagocytosis is primarily mediated by liver 
Kupffer cells while the membrane attack complex (MAC) is a minor mechanism if 
the IgM titre is relatively low. The presence of cold stress increases autoantibody 
activity, facilitating RBC lysis particularly in the extremities. A notable feature of 
CAS is a high variability in hemolysis, and in turn the need for transfusions varies 
greatly from patient to patient.
56
 The degree of hemolysis in CAS patients is 
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primarily dependent on active autoantibody concentration, rather than the more 
abundant membrane bound C3 protein concentration.
56, 57
  
Paroxysmal cold hemoglobinuria (PCH)  
PCH, also known as Donath–Landsteiner syndrome and is a form of cAIHA 
activated primarily by polyclonal IgG antibodies (Donath–Landsteiner antibody). 
Similarly to CAS, PCH activates complement at cold temperatures. Complement 
activation is via P-antigen binding on RBCs with subsequent intravascular 
hemolysis being initiated upon rewarming to normal body temperatures. PCH is 
considered a form of secondary AIHA and typically develops within the first week 
after infection most often seen in children. The infections are primarily upper 
respiratory, and the causative agent is often not identified. Late-stage or congenital 
syphilis was historically linked to cases of PCH in adulthood but this is becoming 
less and less common.
57 
Mixed-type AIHA (mAIHA) 
 mAIHA is characterized by the presence of both warm and cold type 
antibodies as well as both IgG and IgM antibody subtypes. mAIHA accounts for less 
than 5% of the total AIHA incidence, and is even less common in children.
58
 
mAIHA can be both idiopathic or arise secondarily from malignant or autoimmune 
disorders such as SLE or lymphoma. It can be difficult to determine which 
autoantibodies (IgG or IgM) and the required thermal range are causative. Patients 
with mAIHA can have both warm and cold components that can react with different 
antigens. 
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DRUG-INDUCED IMMUNE HEMOLYTIC ANEMIA (DIIHA) 
 DIIHA is relatively rare, may go undiagnosed in many cases, and the 
magnitude of hemolysis can vary widely. There are an estimated 150 drugs known 
to be associated with DIIHA and are categorized by drug-independent (via auto-
antibodies) and drug-dependent antibodies.
59-62
 Drug-dependent AIHA can be 
categorized into two subtypes:  
1) Hapten type which is due to the noncovalent binding of the drug to 
the RBC which is then targeted by the autoantibody in a drug-
dependent manner: 
 2) drug-autoantibody immune (ternary) complexes that are mediated by 
a complement-dependent hemolysis that is drug dependent. 
 Drug-dependent antibody (DDAB) activates a response only while the drug 
is present. This class is the most common case of diAIHA and can be 
mechanistically variable depending on the molecular nature of the drug and its RBC 
interaction. DDAB may specifically attach to the drug, the drug's metabolites, and/or 
drug-RBC neoantigens. Antibiotics cefotetan and high doses of penicillin are the 
best understood mediators of diAIHA. The binding of the DDAB mediates RBC 
phagocytosis via Fc receptor-mediated mechanisms similar to WAIHA with the 
notable difference that the autoantibody binds directly to the RBC in WAIHA and to 
the drug-bound RBC in diAIHA. 
Other drugs such as ceftriaxone and piperacillin interact with the membrane 
of RBCs but bind via RBC neoantigens. It is uncertain how drug binds to the 
membrane and if the complex formed is covalent or loosely bound. The drug and 
RBC membrane form an immune complex mediating DDAB binding to the drug, 
membrane, or equal proportions of the drug–membrane complex.62 
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In contrast drug independent antibodies (DIABs), are capable of creating an 
autoimmune response in the absence of the offending drug. Various mechanisms 
exist by which drugs (i.e. fludarabine, cladribine, and methyldopa) stimulate 
autoantibody formation via adsorption, immune dysregulation, or other mechanisms 
none of which have been fully elucidated. The most common drug usage linked to 
diAIHA is methyldopa, which can continue in a subject months after cessation of the 
drug. The common treatment practice for diAIHA is mediated via blood transfusion 
and discontinuation of the offending agent. Most drugs are cleared from the system 
quickly and the drug-dependent antibodies only persist in the case where there is a 
persistence of RBC membrane-bound drugs.
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ALLOIMMUNE HEMOLYTIC ANEMIA 
Hemolytic Diseases of Fetus and New-born (HDFN) 
The first antibody to be described as a cause of HDFN was anti-D. A 
positive DAT in a new-born result is due to transplacental transfer of IgG antibodies, 
which are present in maternal serum and directed against antigens on fetal and 
neonatal red blood cells (RBCs). Such antibodies may cause destruction of neonates’ 
RBCs and shorten their life span, leading to clinical manifestations of HDN and 
various degrees of hyperbilirubinemia and anemia.
63 
The factors that can lead to a 
positive DAT in neonates
 
are mainly the ABO incompatibility between the new-born
 
and the mother, maternal alloimmunization, and very
 
seldom maternal autoimmune 
hemolytic anemia.
1
 ABO incompatibility
 
with a positive DAT is considered a major 
risk
 
factor for the development of severe hyperbilirubinemia
 
and neurotoxicity.
64, 65
 
By contrast, some studies report that the positive DAT has only a poor predictive 
value for severe
 
hyperbilirubinemia.
68,69
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Hemolytic Transfusion Reactions (HTR) 
The most severe alloimmune hemolysis is an acute transfusion reaction 
caused by ABO-incompatible red blood cells. For example, transfusion of A red 
cells into an O recipient (who has circulating anti-A IgM antibodies) leads to 
complement fixation and a brisk intravascular hemolysis. Within minutes, the 
patient may develop fever, chills, dyspnea, hypotension, and shock. Delayed 
hemolytic transfusion reactions occur three to 10 days after a transfusion and usually 
are caused by low titer antibodies to minor red blood cell antigens. On exposure to 
antigenic blood cells, these antibodies are generated rapidly and cause an 
extravascular hemolysis. Compared with the acute transfusion reaction, the onset 
and progression are more gradual.
70
 
CLINICAL FEATURES 
WAIHA 
Clinical picture of WAIHA is highly variable. Most patients have symptoms 
correlated to anaemia, such as fatigue, palpitations and shortness of breath. 
Occasionally massive haemolysis manifested by haemoglobinuria, haemglobinemia 
and profound anaemia can be seen with secondary WAIHA.
72
 Naithani et al found 
that most common symptoms in their study were related to anaemia.
27
 The 
associated illness often dominates the clinical picture. AIHA may proceed by 
months or even years before the development of diseases such as SLE. Physical 
findings in idiopathic AIHA were pallor, resting tachycardia mild jaundice; fever 
may be present. The spleen is only moderately enlarged.
74
 Pallor was universal 
finding in 98% of patients.
2 
Evidence of hemolysis was established with peripheral blood spherocytosis 
and fragmented cell, with elevated reticulocyte count, erythroid hyperplasia in the 
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marrow, unconjugated hyperbilirubinemia, and a positive direct antiglobulin test 
(DAT) with or without indirect antiglobulin test (IAT). 
COLD AIHA 
They often present with symptoms of chronic anaemia. Episodes of acute 
hemolysis occur after cold exposure, which is presented as haemoglobinuria, 
haemglobinemia.
73 
The clinical course of Cold AIHA is characterised by either 
chronic anaemia or episodes of haemolysis, depending upon the thermal amplitude 
of the cold agglutinin.
23
 In children, PCH appears 1 to 2 weeks after an episode of 
upper respiratory tract infection. Usually, the onset of haemolysis is signalled by a 
recurrence of fever and then the passage of reddish brown urine.
2  
Evaluation for DIIHA should be assessed by a careful history of drug 
exposure in every patient with AIHA and/or a positive DAT. In general patients with 
hapten/drug absorption (i.e. penicillin) and autoimmune (i.e. methyldopa) types of 
diAIHA exhibit mild to moderate hemolysis, with insidious onset over a period of 
days to weeks. In contrast, the immune or ternary complex-mediated DIIHA (i.e. 
cephalosporins or quinidine) typically is associated with a sudden onset of severe 
hemolysis and hemoglobinuria.
60-62
 
The diagnosis of anaemia on the basis of physical signs is remarkably 
difficult and the classic observation of pallor is quite unreliable. Jaundice is most 
common presenting sign in 39% of the patients in pirofsky’s series.41 Allgood and 
Chaplin reported that Splenomegaly was present in 57% of the patients with 
idiopathic AIHA.
51
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HDFN 
Features of hemolysis are in the form of anaemia (cord HGB3.5-8g/dl), 
Jaundice and hepatosplenomegaly along with positive DCT.
63 
THE ANTIGLOBULIN TEST 
Red cell coated autoantibodies and alloantibodies are gamma globulins, 
usually IgM, IgG, IgA, or complements such as C3d, C3c. If they are IgM, they 
usually directly agglutinate saline-suspended RBCs. In contrast, IgG antibodies 
often do not agglutinate RBCs but react with the corresponding antigens on the RBC 
membrane, giving a “sensitized” RBC. Thus, chemically speaking, the RBCs are 
sensitized with gamma globulin. The AHG will combine with it, crosslinking the 
sensitized RBCs and causing agglutination. Anti-IgG reacts mainly with the Fc 
portion (i.e., heavy chains) of human IgG molecules present on the RBCs. The 
heavy chains are specific for each class Antibodies, however antibodies to light 
chains may be present in polyclonal AHG as well; in a polyspecific AHG, this has 
no disadvantages and theoretically may be an advantage by forming extra “bridges” 
across adjacent light chains and the polyspecific AHG can pick up other 
immunoglobulins such as IgM, and IgA;. 
In 1946, Boorman and coworkers
73
 and Loutit and Mollison
74
 reported that 
the RBCs from patients with idiopathic acquired hemolytic anemia reacted with 
AHG. The first application of the test (i.e., detection of Rh antibodies in serum) 
became known as the indirect antiglobulin test (IAT),
1
 and the second application 
(i.e., detection of in vivo sensitization) became known as the DAT.
75,76 
However, 
IgM sensitization of RBCs is difficult to detect with the AGT;
72,73
 furthermore, IgM 
antibodies that cause immune hemolytic anemia characteristically, if not invariably, 
fix complement, which is much more readily detected.
74
 IgA antibodies only 
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infrequently play a role in RBC sensitization, and in such cases, other immune 
globulin and/or complement components are almost always, although not invariably, 
found on the RBC surface as well.
81-82
 
DAT with a polyspeciﬁc antiglobulin serum, which is deﬁned as one that 
must contain anti-IgG and anti-C3d and may contain antibodies to other complement 
components (e.g., C3b, C3c, and C4) and to other immunoglobulins (e.g., IgA and 
IgM). A positive result in a patient with acquired hemolytic anemia generally 
indicates that the patient’s RBCs are coated with IgG, C3dg, or both. Using 
monospeciﬁc anti-IgG and anti-C3, it is then a simple matter to determine which of 
these two proteins are coating the patient’s RBCs. DAT with an antiglobulin serum 
that does not contain anti-C3d will frequently result in misleadingly negative results 
in patients with IHAs. This is true in all patients with CAS, 13% of patients with 
WAIHA, essentially all patients with PCH, and many instances of drug-induced 
IHAs. 
 The direct antiglobulin test (DAT) should be performed in every patient in 
whom the presence of hemolysis has been established. Although some exceptions to 
this rule might be considered, as when the diagnosis of a congenital hemolytic 
anemia is evident, the DAT is a simple, quick, inexpensive test that yields useful 
information. A positive result on a DAT in a patient with hemolytic anemia does, of 
course, indicate that the most likely diagnosis is one of the immune hemolytic 
anemias. The predictive value of positive DAT is 83% in a patient with immune 
hemolysis, but only 1.4% in patients without immune hemolytic anemia.
3
  
Original DAT method by CTT able to detect a lower limit of 150 to 200 IgG 
molecules per RBC
72
 and 400 to 1100 C3d molecules per RBC.
4
 with introduction 
of GT in 1990 by Lapiere et al, the method gained importance in laboratory practice 
of immunohaematology in developing countries including India.
76
 Gel cards for 
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detailed serological characterization of auto and alloantibodies are available. The 
GT had been reported to be more precise and sensitive than widely practiced 
CTT.
79,80
 A small number of studies concluded that GT showed lower sensitivity 
mainly in detection of C3d coated red cells. 
 Severity of haemolysis was correlated with the number of antibodies bound 
to the RBC and the strength of DAT.
80,81
 A positive DAT did not always mean 
decreased RBC survival. Many studies found out the relationship between the 
presence or absence of hemolysis and the DAT strength was highly statistically 
significant.
77,78
 S S Das et al, from India also observed a significant correlation 
between strength of DAT and severity of hemolysis. The predictive value of a 
positive DAT was 83% in the patients with IHA, but only 1.4% in the patients 
without IHA.
 14
 Dorothy Dinesh in her study indicates that the sensitivity of a 
positive DAT for clinically significant HDN is 85%.
9
 Huub H.vanRossum et al 
estimated the positive predictive value (PPV) calculated was 10% for DAT and 
eluate.
83
 It should be emphasized that determination of the presence or absence of 
hemolysis, should logically precede the performance of the DAT. 
 
Therefore, interpretation of DAT must be done along with clinical history 
and other laboratory findings. Further evaluation of a positive DAT in a patient with 
clinical and laboratory evidence of haemolysis includes testing for clinically 
significant antibodies to RBC antigens and testing an eluate.
61
 A significant 
correlation between small increases of cell bound immunoglobulins and haemolysis 
was shown in 25% of patients with evidence for immune mediated haemolysis.  
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ELUTION  
Discovery of Elution Technique  
 The first antibodies coating RBCs elution technique for cold antibodies is the 
heat elution discovered by Landsteiner and Miller as early as 1902. Landsteiner was 
also instrumental in developing the second technique for eluting antibodies from 
RBCs. In co-operation with van der Scheer, he created a method for dissociating 
azostromato-antibody complexes. This method was modified by Kidd, he eluted the 
antibodies by exposing stroma to citrate buffer having a pH of 3.2 to 3.4 at room 
temperature.
84, 85
The freeze-thaw is Weiner’s method that destroys RBCs, 50% cold 
ethanol used for precipitating the stroma and recovering antibody from the 
precipitate stroma with saline 37°C.
83
 For testing IgM antibodies eluates, 
hemoglobin-free elute are important but they are not essential for indirect 
antiglobulin tests (IAT).
84
 For this objective, Harry Rubin created the ether elution 
method at 37°C for warm antibodies; in addition some observations were made on 
the sensitized red blood cells of patients with autoimmune hemolytic anemia.
86
 
Rubin’s ether elution method is dangerous for the blood bank worker. Ether is 
highly flammable and must be strictly regulated in regard to its use and storage.
87
 
Rekvig and Hannestad and Bush created glycine-HCl elution method for use with 
intact RBCs instead of stroma.
88
 And these two creations have been developed to 
modern commercial elution kits such as Elu- Kit II, Gamma Biological Inc. 
Houston, TX and DiaCidel Elution Kit, DiaMed AG, Switzerland.
89
 Another elution 
method was described by Chan-Shu and Blair, by Bueno R. al using xylene that 
elution technique was superior to methods using ether, digitonin-acid and heat.
90 
In recent years, various methods of antibody dissociation have been 
developed that do not destroy the RBCs. The objective is to remove either IgM or 
IgG autoantibody in a way that permits accurate phenotyping of the RBCs. Three 
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methods have been developed to permit phenotyping of IgG-coated RBCs with 
reagent antisera require using by the Indirect Anti human globulin test. The first, 
Edward et al have Investigated the quinolone derivative chloroquine diphosphate 
(200 mg/ml, pH 5.0) to dissociate antibodies without denatured red cell antigens. 
They found the chloroquine dissociation technique to be of value in the examination 
of red blood cells with a positive DAT, either or the qualitative or quantitative 
expression of antigen.
91
 The second, other investigators studied the effect of acidic 
ethylene diamine tetra acetic acid (EDTA)-glycine mixtures to remove IgG from 
RBCs without destroying RBC antigens. The third, Caruccuo L. et al found that the 
formamide method was efficient in removing antibodies from RBCs. The patient 
samples with a positive DAT had antibodies recovered with the same specificity 
when compared to the acid-based technique.
85
 The preparation time length was 
similar for both formamide and acid based methods.
85, 86, 88 
 Approximately 80% of the patients with AIHA have autoantibodies in their 
serum as well as on their RBCs.
9
 The antibodies in the serum or plasma and the 
antibodies eluted from RBCs were detected by IAT(i.e antibody screening).
93
 Many 
panagglutinins were believed to react with a basic determinant of the Rh antigen 
system, as they fail to react with Rh null RBCs which has no Rh antigens on them.
93
 
Warm autoantibodies are mostly panagglutinins, reacting with every cell in the 
diagnostic RBC panel. 
 Elutions were not typically performed on DAT positive only for 
complement, as these molecules would not be expected to have antigen binding 
specificity. However, elution tends to produce a more concentrated antibody 
solution, hence the reactions are stronger.
11
 Autoadsorption and antigenic 
phenotyping could help in differentiating autoantibodies and alloantibodies, 
especially if the patient had not been transfused recently.
94
 Wikman A et al had 28% 
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of alloantibodies in AIHA patients all of them fell in moderate hemolysis group.
77
 
Similarly the study conducted by Branch DR and Petz LD 25-47% of sera from 
AIHA patients showed the presence of alloantibodies.
139 
Autoadsorption could also be used to cross match donor RBC units or 
patients with warm autoantibodies (only for the patients who have not been 
transfused recently).
11 
FACTORS THAT INFLUENCE THE OUTCOME OF ELUTION 
  1. Incomplete washing  
2. Dissociation of antibodies prior to elution  
3. Storage changes to organic solvents.  
4. False-positive eluates with acid elution kits.  
5. Antibody binding to glass surfaces.  
APPLICATIONS OF ELUTION 
1. In the initial evaluation of samples suspected to contain warm 
autoantibodies. To report the antibodies as "auto," one must demonstrate 
either that the antibody can be eluted from the patient's RBCs or that they are 
adsorbed by those RBCs. Once autoantibodies have been demonstrated by 
elution, there is no need to repeat the elution study each time a sample is 
submitted for DAT. 
2. In the evaluation of a positive DAT/autocontrol that is performed as part of 
an antibody identification study. Even here, elution studies should be 
restricted to instances in which the patient has been recently transfused and 
serum studies are inconclusive. Rarely will elution studies reveal an 
alloantibody that is not readily detectable in the serum.  
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3. When there are clinical signs and symptoms of immune hemolysis. Elution 
studies can be informative even when the DAT is negative, as in "Coombs-
negative" autoimmune haemolytic anemia, or sometimes in the investigation 
of a delayed hemolytic transfusion reaction. 
4. In the evaluation of suspected haemolytic disease of new born (HDN), when 
screening tests for unexpected antibodies on maternal serum are nonreactive, 
and paternal RBCs are ABO incompatible with maternal serum. Testing an 
eluate prepared from the infant's cells against the paternal RBCs may 
indicate a maternally derived alloantibody to a low-prevalence paternal 
antigen. Blood also may be cross matched against an eluate when the infant 
needs an exchange transfusion and maternal serum is unavailable.  
5. Phenotyping red cells in patients with a positive DAT. 
TYPES OF ELUTION METHODS 
Heat 
An increase in temperature results in displacement of the equation to the left, 
dissociation of [AgAb] at the molecular level, heat increases the thermal motion of 
atoms and molecules, leading to dissociation.  
An increase in heat also causes conformational changes to proteins, leading 
to loss of structural complementarity. At 56˚C denaturation of RBC membranes 
occurs, as evidenced by the haemoglobin stained eluates prepared by the method of 
Landsteiner and Miller. Calvin et al., and others have shown that RBCs incubated at 
56˚C for 5 minutes lose their Rh antigens. Incubation of RBCs at 56˚C for 10 
minutes destroys Fya and Jkb antigens, and weakens the expression of M and P1 
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antigens. Membranes isolated from the treated RBCs give an abnormal 
electrophoretic pattern when subjected to polyacrylamide gel electrophoresis. 
Freeze-Thaw 
Extracellular ice crystals that form as RBCs freeze attract water from their 
surroundings. This increases the osmolarity of the remaining extracellular fluid, 
which then extracts water from the RBCs. The ice crystals cause the RBCs to shrink 
in size and also mechanical damage to RBC membranes which results in cell lysis. 
Some dissociation of antibody may occur because of changes in the ionic strength of 
the extracellular fluid and rearrangement of water molecules at the cell surface. 
Disruption of RBC membranes undoubtedly leads to denaturation of antigens, some 
of which may be shed from rigid cell membranes; such rigidity can be presumed to 
exist with RBCs at sub-zero temperatures.  
The only tenable explanation for the mechanism of antibody elution by the 
Lui freeze-thaw method is one of conformational changes to membrane structures 
resulting from the dramatic and rapid changes in temperature that is inherent in this 
technique.  
Sonication 
High-frequency sound waves cause a rapid alternation in pressure within 
liquids, causing formation of minute gas bubbles. When they reach a critical size, 
they implode. The produced shockwaves exerts considerable shearing forces. 
Antibody molecules are shaken off the RBCs. The considerable amount of heat 
produced during sonication, resulting from the implosion of the gas bubbles, will 
also contribute to antibody dissociation. 
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pH Changes 
Proteins become either negatively charged at a high pH (anionic state) or 
positively charged at a low pH (cationic state). In either state, proteins lose their 
ability to attract one another through electrostatic bonding and may actually be 
forced apart by repulsion of like charges. H + ions and OH- groups,which abound in 
low- and high-pH solutions, respectively, are attracted to opposite charges on polar 
amino acids such as lysine, arginine, and histidine (positively charged R groups), 
and aspartic and glutamic acids (negatively charged R groups). This causes changes 
to the tertiary structure (molecular unfolding) of proteins, and at extreme alkaline 
pH levels, the secondary structure of proteins may be affected by disruption of their 
peptide bonds. 
Chaotropic Ions 
Cl-, I-, and SCN- ions literally cause chaos to proteins. They bind to charged 
groups on amino acids that govern the tertiary structure of proteins. Thus, molecular 
unfolding and even disruption of peptide bonds can occur when proteins are 
suspended in solutions of salts that include these ions. At high salt concentrations, 
the "salting-out" of proteins occurs, which involves inward folding of polypeptides 
and leads to a decrease in protein solubility. Thus, Chaotropic ions cause 
considerable conformational changes to proteins. With respect to the effect of 
chaotropic ions on the forces involved in the first stage of hemagglutination 
reactions, electrostatic shielding of charged groups by counterions leads to 
weakening of the forces of attraction between antigen and antibody. Also, because 
solutions containing high concentrations of salts can attract water from a place of 
lower salt concentration, there may be some rearrange merit to the ordered water 
molecules at the RBC surface. This will undoubtedly influence the hydrophobic 
effect involving van der Waals interactions. 
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Organic Solvents 
Organic solvents, such as ether, denature or destroy antigens, whereas 
antibody molecules are not affected. This occurs by dissolution of the RBC 
membrane bilipid layer. They demonstrated that the forces of attraction arising from 
van der Waals interactions can be changed to forces of repulsion when the..J surface 
tension of the liquid medium stir rounding the RBCs is lowered to a point between 
the surface tension of the antigen and its binding site on an antibody molecule. 
Although performed the tests using DMSO, other organic solvents (ether, xylene, 
chloroform, etc.) likely exert a similar effect. 
Chloroquine Diphosphate 
RBCs suspended in chloroquine diphosphate have a reduced electrophoretic 
mobility. Antigens mad antibodies are not denatured, and normal electrophoretic 
mobility is restored after chloroquine removal. Thus, it appears that the effect of 
chloroquine may be one of neutralization of charges by counterions, similar to but 
milder than the effect of chaotropic ions.  
Thiol Reagents 
It is well known that the sulphydryl compounds DTT and 2-ME disrupt 
interchain disulfide bonds of pentameric IgM. The spontaneous agglutination of 
RBCs coated with cold autoantibodies is abolished simply because the IgM 
molecules on the RBCs fall apart. Similarly, IgG warm autoantibodies can be 
removed from RBCs by adding either ficin or papain to DTT (ie, ZZAP reagent). 
These enzymes cleave IgG molecules at a protease sensitive site just below the 
hinge-region, thereby exposing the intrachain disulphide bonds to the action of DTT. 
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Ole Petter Rekvig and Kristian Hannestad in their study Acid elution of 
blood group antibodies from intact erythrocytes describes that Elution of antibodies 
from intact human and sheep erythrocytes at pH 3.0 than heat elution and ether 
elution. They concluded that acid elution at pH 3.0 gave the highest yield out of the 
three methods.
88 
 Rahul Katharia and Rajendra K. Chaudhary in their study demonstrated that 
Heat elution was equally potent as Glycine-HCl/EDTA in removing antibodies from 
in vitro sensitized red cells, decrease in DAT positivity was not as effective on in 
vivo-sensitized red cells and red cells coated with autoantibodies. Chloroquine di 
phosphate was effective in removing antibodies attached from sensitized intact red 
cells. It is not as potent as Glycine-HCl/EDTA and heat elution. They concluded that 
Glycine-HCl/EDTA elution method was more effective in reducing strength of 
reaction in both in vivo and in vitro sensitization.
8 
Huub H.vanRossum et al., study explains the high sensitivity of both 
techniques (DAT and Elution) on detecting neonatal erythrocytes sensitized with 
anti-A and anti-B. Especially for A/O-incompatible pregnancies it appears that some 
degree of sensitization of neonatal erythrocytes with maternal IgG anti-A occurs 
regularly. “sub clinical” erythrocyte sensitization results in a low positive predictive 
value and specificity for both DAT as well as eluate screening. Screening for HDN 
by DAT results in many false positive results. In cases of ABO-incompatible 
pregnancies large percentages of positive neonatal DAT results are observed in the 
absence of clinical jaundice.
83 
 Elie Richa et al found that Micro+ DATs yielded a lower rate of new 
antibody detection (5.5%) than the combined groups of macroscopically positive 
DATs, 12.2% (p = 0.047). They concluded that eluate testing in the setting of 
micro+ DATs should not be a standard practice.
95
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R.H. Finck et al., performed elution with Glycine acid/Elu-kit II in DAT 
positive cord samples. Antibodies were eluted from all DAT positive cord blood 
RBCs (2 Jk
a
 and 5 ABO HDFN). No antibodies were detected in the last wash fluids 
by either method for all cord blood samples included in the study. They concluded 
that apart from ABO HDFN all other antibody mediated HDFN can be diagnosed 
antenatally. However, Elution can be of useful value in diagnosing clinically 
significant ABO HDFN and difficulty in obtaining maternal serum for other 
HDFN.
96 
Marilyn Johnston FM, Mary Kay Belota, observed that 68% of patients, in 
which 37% yielded positive eluates and 63% had nonreactive ones. Of the positive 
elution studies, 73% demonstrated only warm autoantibody on red blood cells. 2.5% 
of these had warm autoantibody in serum as well. 3% of these specimens were from 
previously transfused patients and had alloantibody/ies in serum. They concluded 
that positive DAT investigation and elution studies appear to be clinically helpful in 
investigating delayed hemolytic transfusion reactions and identifying implicated 
alloantibodies.
97 
SPECIFICITIES OF ANTIBODIES IN ELUATE 
Wiener and coworkers suggested that 37°C-reactive (“warm”) autoantibodies 
might be directed against the “nucleus of the Rh-Hr substance”.98  Pirofsky and 
Pratt, in 1966, compared the reactions of alloanti-Rh and “warm” autoantibodies 
with RBCs from a large variety of primates and non-primates and essentially agreed 
with the findings of Wiener and coworkers.
99
 
Autoanti-e was the most common reported specificity; it has been pointed 
out that the reported relative incidence of different specific Rh autoantibodies 
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corresponds well with the incidence of Rh antigens in the population (i.e., e is 
present on the RBCs of approximately 98% of the population).
39
 
COLD AIHA 
The main group of antigen recognized by human cold agglutinins (Cold 
AIHA) have been defined on a serological and biochemical basis. It is mainly the Ii 
antigens. They are protease- and sialidase-resistant differentiation antigens. I antigen 
is fully expressed on adult and i antigen is fully expressed on fetal RBCs. Anti-i 
recognizes linear poly- N-acetyl lactosamine or type 2 chains, which are converted 
into I antigens in the first year after birth by branching. Jenkins and coworkers found 
that sera containing cold autoagglutinins that had previously been called 
“nonspecific cold agglutinins” had anti-I specificity and it is more common to other 
cold autoantibodies.
100 
HEMOLYTIC TRANSFUSION REACTIONS (HTR) 
Based on the study done by Grove and Rasmussen
 
the most common 
antibodies to cause HTR were anti-K, anti-E. The next most common antibodies 
were anti-Fya, anti-c, and anti-Jka.
101
 The Mayo Clinic’s 10-year study also found 
anti-K to be the most common cause of HTR. They found that second common 
antibody was anti-Jka and anti-Fya was equal to anti-E as the third most common 
offenders.
 102-105 
When DHTRs were examined separately, anti-Jka and anti-E were found to 
be the cause of HTRs more often than anti-K. Anti-Jka and anti-E were followed by 
anti-K and anti-Fya, respectively, as causes of DHTR. 
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HDFN 
Historically, the next most common antibody after anti-D was anti-E, 
followed by anti-c, -Jka, and -K, followed by anti-C, -s, -e, -cE, -Fya.
106 
 In 1964, Giblett reported that 93% of antibodies detected in sera of pregnant 
women were anti-D (or anti-C+D).
107
 Kornstad et al.,
 
reported that in Norway, the 
occurrence of new cases of anti-D had fallen from 0.6% to 0.2%.
108
  
Mollison et al., The commonest IgG red cell antibodies in human serum are 
anti-A and anti-B, although, relatively high concentrations are found only in group 
O subjects. Although ABO haemolytic disease is common, relatively few infants are 
severely affected; the proportion is higher in some populations than in others. 
Haemolytic disease due to anti-D tends to be more severe than haemolytic disease 
due to anti-c. As a cause of death from haemolytic disease, anti-K is next in 
importance after anti-c.
109 
TITRATION 
After test findings suggest CAD, the antibody titer and thermal activity 
should be determined.
 
The latter is essential to prevent over-diagnosis, because most 
agglutinins are clinically insignificant.
 110 
G. Garratty, L. D. Petz and J. K. Hoops IN 
THEIR study of CAS, the cold agglutinin titres (CAT) at 2°C were found to range 
from 1024 to 12 000, the upper thermal limit for agglutination in vitro being 25-
37˚C. Most of the sera had titres between 2000 and 64000 and reacted up to 28-
32°C. It should be noted that all these tests were with saline suspended red cells.
111
 
According to Pirofsky (1969), 'The diagnosis of cold hemagglutinin disease is 
dependent on demonstrating a cold acting erythrocyte autoantibody that differs in 
two fundamental aspects from those seen in normal serum. Titres are generally 
elevated over 500 at 0˚C; in normal serum, the cold hemagglutinin titre rarely 
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exceeds 64. In general a high thermal reactivity of the pathologic cold acting 
erythrocyte autoantibody is also observed.
99 
One study showed only 8% of patients with cold agglutinins displaying 
clinically significant activity.
112
 The titer level is less concordant with disease 
activity because hemolysis occurs with levels as low as <1:32
113
 however, most 
consider titer levels greater than 1:512 as clinically significant.
112
 Berentsen et 
al reported a median titer of 1:2048,
114
 whereas Stone and colleagues observed titers 
from 1:512 to 1:65 536.111 After CAD is established, patients should be evaluated 
for infections, underlying malignancies, and autoimmune disease because more than 
70% of cases may be attributable to these processes.
111,113
 
 Hopkins C and Walters TK in their study says that the thermal amplitude 
test is performed to determine the reactivity of a cold autoantibody at varying 
temperatures: 4° C, 22° C, 30° C, and 37° C. Cold autoantibodies that are reactive at 
temperatures greater than 30° C have the potential to be clinically significant 
regardless of the antibody titer. Cold antibodies that are reactive at temperatures less 
than 30° C are not considered to be clinically significant.
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MANAGEMENT OF AIHA 
Patients with mild and compensated hemolysis did not require any 
treatment.
70 
Patients with AIHA, who presents with severe anemia are in need of 
blood transfusion. 
2
 A diagnosis of AIHA is often made in blood transfusion services 
when autoantibodies are detected during the compatibility testing. Transfusion of 
patients with AIHA presents with unique set of problems.
116
 The indications for 
transfusion must be considered in light of following facts: 
 The risks of transfusion are somewhat increased due to the difficulty 
of compatibility testing. 
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  The patient’s autoantibody can be expected to cause a shortened life 
span of transfused red blood cells (RBCs).
117
 
Nevertheless, blood should never be denied to a patient with a justifiable 
need even though the compatibility test might be strongly positive.
117-119
 A major 
difference between transfusing patients with AIHA and those without RBC 
autoantibodies is that the clinician must consider the time that is required by the 
transfusion services to do complex serological tests to assure that optimal red cell 
product is obtained.
2 
The clinician and the transfusion service must be in contact 
with one another so that the transfusion service understands the urgency of the 
situation and the clinician understands the complexity of the serological studies to be 
undertaken.
120
 The serological investigations are usually time consuming, notifying 
the need for transfusion and initiation of AIHA workup as early as transfusion 
considered is essential for the successful management of the severely anaemic 
AIHA patients.
121
 Finally, it should be emphasized that the decision to transfuse 
must not depend on the serological findings but rather it should be on the patient’s 
clinical status.
2
 One of the common mistakes in the management of AIHA is the 
reluctance to transfuse even those with severe anemia. Such cases had been reported 
by conley and associates.
122,123 
In patients with AIHA and moderate anaemia, the 
physician should note whether the patient appears acutely ill suggesting of acute 
hemolysis or compensated gradual loss of RBCs.
124
 50% of patients with WAIHA 
will respond to adequate doses of corticosteroids during the first week of therapy. 
Acute PCH seldom lasts longer than 7 to 10 days.
125
 The hazards and inconvenience 
of long term transfusions must be considered. It is preferable to live with mild 
symptoms of anaemia rather to face the hazards of long-term transfusion therapy.
126 
The RBC autoantibody might react strongly in vitro (eg., 2+ to 4+ in IAT) 
with all available donor units, thus making the selection of compatible blood for 
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transfusion impossible. Nevertheless, acute transfusion reactions occur only 
infrequently. In very rare instances, they develop significant complications such as 
post transfusion haemoglobinuria, acute renal failure
38, 127
 or disseminated intra 
vascular coagulation.
128, 129
  
The term least incompatible is not an official term in transfusion medicine 
and is not defined in medical literature.
130
 It appears to mean that the selection of a 
unit of blood which gives weaker reactions in the compatibility testing than other 
incompatible units. This implies, one may perform cross matching using a number 
of ABO and Rh matched donor units with the patient and finally select the unit that 
reacts least strongly. The rationale for using “least incompatible” units appears to be 
that the stronger reactions could be caused by an alloantibody.
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Although the donor blood appears to be compatible, the transfused RBCs 
cannot be expected to survive normally. Mollison has stated that in all those 
conditions in which a hemolytic anemia was due to some extrinsic mechanism rather 
than any intrinsic defect in the RBCs, transfused normal RBCs were expected to 
undergo accelerated destruction.
109
 As pointed out by Leger and Garratty, patients 
who had autoantibodies should receive the same protection from haemolytic 
transfusion reaction reactions as other patients.
131 
American Association Blood 
Bank’s standards indicates that if a patient had received a transfusion or been 
pregnant within the preceding 3 months, then the sample must be obtained from the 
patient within 3 days of scheduled transfusion.
132
 some investigators suggest that the 
transfusion of RBCs that are prophylactically antigen matched with the patient’s, 
rather than performing adsorption studies to detect alloantibodies.
133
 Providing 
phenotypically matched blood can provide significant measure of safety.
134 
The one aspect of therapy about which there is a uniform agreement is that 
corticosteroids should be an initial therapeutic tool in treating patients with AIHA of 
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warm antibody type.
2
 Data in the older medical literature indicates that the initial 
response was often excellent, with about 80% of patients experiencing prompt 
reduction in RBC destruction.
40,48,134-136 
The onset of the response was usually rapid. 
Significant haematological improvement is often evident within a few days and most 
patients demonstrate benefit within 10 to 14 days.
137,138
Although one might be 
tempted to discontinue steroids more rapidly, recurrences seem to be more likely 
unless the patients were treated for a minimum of 3 to 4 months with low doses of 
corticosteroids following subsidence of an acute episode of hemolysis.
139,140 
splenectomy had a distinct advantage over other therapeutic options in that it offers 
the potential for complete and long term remission. The available data suggests that 
the splenectomy is helpful in complete and long term remission of 50% of WAIHA 
patients.
137
 Transfusions are usually transient benefit but might be required initially 
because of severity of anemia until the effect of other treatments takes place.
2
 In 
severe hemolysis with significant anemia treatment with corticosteroids was 
initiated.
72
 When anaemia is severe in spite of steroid therapy IvIg might be tried. 
Azathioprin and Rituximab had been useful in chronic refractory cases.
116
  
Childhood AIHA up to 77% of cases are self-limiting, requiring only short 
term therapy. First line of therapy is corticosteroids, prednisolone starting dose of 
2mg/kg/day with response rate of 81% to 100% of children with primary and 
secondary AIHA. Children compensate better for falling Hb. Hence, transfusion 
support is usually avoided until there are signs of cardiac compensation. Tests for 
additional immunological diseases such as autoimmune lymphoproliferative 
syndrome and a primary immunodeficiency should be done before starting 
treatment. 
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MATERIALS AND METHODS 
 
STUDY DESIGN 
This cross sectional study was carried out in the Department of Transfusion 
Medicine and Immunohematology, The TN Dr.M.G.R Medical University, Chennai 
and Department of Hematology, Madras Medical College, Chennai. 
STUDY POPULATION 
In this study, patients with clinical and laboratory evidence of hemolysis 
with Direct Antiglobulin Test Positive Results were included. 
STUDY PERIOD 
This study was done over a period of one year spanning from August 2017 to 
September 2018. 
SAMPLE SIZE 
All DAT positive Immune hemolytic anemia cases and samples received 
during the Study period. (Purposive Sampling) 
STATISTICAL ANALYSIS 
Mean, median, Range and standard deviation was calculated for all 
continuous variables. Pearson and fisher’s exact chi square test was done to compare 
the categorical data. Mann-Whitney’s test is used to calculate p value of HGB, 
Bilirubin, LDH and reticulocytes. Binary logistic regression analysis was used for 
comparing categorical data and to calculate the odds ratio with 95% confidence 
interval (CI). p value < 0.05 was considered significant. 
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INCLUSION CRITERIA 
1. Patients with clinical and laboratory evidence of hemolysis with positive 
DAT. 
2. Patients who are willing to participate in the study. 
EXCLUSION CRITERIA 
1. Patients with evidence of hemolysis, but DAT negative. 
2. Patients who are not willing to participate in the study. 
This study was carried out in the Department of Transfusion Medicine The 
TN Dr.M.G.R Medical University, Chennai and Department of Hematology Rajiv 
Gandhi Government Hospital, Chennai. All DAT requests received during the study 
period (i.e.) August 2017 to September 2018 were evaluated for the study eligibility. 
All samples were received for DAT in Ethylene Diamine Tetra Acetic acid 
(EDTA) tube/Vaccutainers. Blood grouping and Rh typing was done by tube 
technique. Polyspecific DAT was performed by CAT using LISS Coombs ID card 
“DAT IgG/C3d” which can detect IgG and C3d.  
The blood samples of the patients’, who could potentially be included in the 
study, were temporarily stored at room temperature 37
0
C and samples were 
processed within 24 hours of collection.
7 
Patients who had positive polyspecific DAT results were further evaluated 
by using monospecific LISS Coombs ID card “IgG, IgM, IgA, anti C3d and anti C3c 
” which could detect the presence of anti-IgG, anti-IgM, anti-IgA, anti-C3d and anti-
C3c. If monospecific cards are positive, further IgG subtyping was performed using 
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anti human globulin IgG1 and IgG3 by CAT from BIORAD and this was done in 
two dilutions of 1:1 and 1:100.  
Further, to find out the specificity of the antibody, elution studies were 
carried out using Glycine acid elution and Glycine acid /EDTA elution procedures. 
Autoadsorption was carried out in AIHA samples having IAT more than or equal 
that of DAT. 
AIHA is further classified into Primary and Secondary AIHA based on 
history, laboratory and radiological results. 
The degree of severity of AIHA was classified into moderate or severe based 
on following laboratory parameters. 
1. Hemoglobin < 9gm/dl 
2. Unconjugated Bilirubin >2mg/dl  
3. LDH > 500 IU/ml and 
4. Reticulocytes >2% 
For HDFN  
1. HGB < 14gm/dl and 14-18gm/dl.160,109 
2. Uncojugated bilirubin >15mg/dl and <15mg/dl.67,109 
The hemolysis is classified into severe if all the above said parameters were 
fulfilled and classified into moderate on the basis of whether two or three of the 
above said laboratory parameters mentioned above are abnormal.
14,77,78
  
The study algorithms are shown below: 
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ALGORITHYM FOR DAT POSITIVE AIHA CASES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ELUTION 
Acid elution or Glycine     
           Acid /EDTA 
g 
Subclass IgG1/IgG3 (DAT) 
 
Monospecific DAT 
IgG, IgM, IgA, C3c, C3d 
Blood grouping & Typing 
 IAT, Autocontrol 
Polyspecific DAT 
DAT positive AIHA cases 
Antibody Specificity 
Antibody Screening & 
identification of ELUATE 
H/O transfusion or 
Pregnancy  
IAT positive > DAT positivity 
AUTO ADSORPTION 
Antibody screening and 
identification  
Alloantibody Identification 
ISSUE of compatible/ 
phenotype matched 
blood to the patients 
Thermal Amplitude  
Cold agglutinin titre 
ALGORITHM FOR DAT POSITIVE DHTR CASES 
 
 
 
  
Immune hemolysis 
with H/o Tx 
DAT +ve 
Perform Antibody 
screen in pt serum 
Antibody screen +ve 
Do identification 
Patient’s Ab Screen 
Negative 
Do elution on 
patient’s RBCs 
Do Antibody screen & 
Identification with 
eluate 
 
Do Elution on 
patient’s cells 
Do Antibody screen & 
Identification with eluate 
MonospecificDAT 
IgG1&3 sub class 
ALGORITHM FOR DAT POSITIVE CORD RED BLOOD CELLS (HDFN) 
 
 
 
DAT results on 
Cord RBCs 
DAT +ve 
Perform Antibody 
screen on mother 
Antibody screen +ve 
Do identification 
Mother Ab Screen 
Negative 
Neonate ABO 
incompatible 
Do elution on Cord 
RBCs 
test with screening 
cells and reverse cells 
Do Elution on Cord 
cells 
Do Antibody screen 
& Identification  
MonospecificDAT 
IgG1&3 sub class 
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LABORATORY PROCEDURES 
1. Specimen collection. 
2. ABO blood grouping by tube method. 
3. Rh typing by tube method.  
4.  Direct Antiglobulin test by poly specific Anti Human Globulin 
(AHG) reagent by Gel Method. 
5.  Direct Antiglobulin Test by mono specific reagents by Gel method 
(anti IgG, anti IgA, anti IgM, anti C3c, anti C3d). 
6. Determination of IgG subclasses by Anti-IgG1 and Anti-IgG3 
reagents by Gel Method 
7. Thermal Amplitude Test. 
8. Cold autoantibody titration. 
9. Elution studies done by Glycine Acid method. 
10. Elution studies done by Glycine Acid EDTA method. 
11. Determining the Specificity of Cold-Reactive Autoagglutinins. 
Method 1: Sample collection procedure  
Skin over the venepuncture site is cleared with 70% isopropanol and allowed 
to dry spontaneously. After applying tourniquet, 10ml of blood was withdrawn from 
antecubital vein by means of 10cc syringe and 23 gauge needle into EDTA and plain 
vaccutainers. Serum and red cells are separated by centrifuging at 3000rpm for 
3minutes. 
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Method 2: Determination of ABO Group of Red Cells and Serum (Tube) 
Reagents 
Monoclonal anti-A, anti-B, anti-AB and A1, B, O pooled red cells. 
Procedure 
1. Place 1 drop of anti-A, anti-B, anti-AB in corresponding clean, labelled test 
tubes.  
2. To each tube, add 1 drop of a 2-5% suspension (in saline) of the red cells to 
be tested. 
3. Gently mix the contents of the tubes; then centrifuge to 1000rpm for 1 
minute. 
4. Gently resuspend the cell buttons, and examine them for agglutination. 
5. Read, interpret, and record the test results. 
6. Compare the red cell test results with those obtained in the serum or plasma 
tests. 
Serum Grouping 
1. Add 2 or 3 drops each of serum or plasma to three 
2. Clean, labelled test tubes 
3. Add 1 drop of 2-5% A1 Pooled red cells to the tube labelled A1cells. 
4. Add 1 drop of 2-5% B pooled red cells to the tube labelled B cells. 
5. Add 1 drop of 2-5% O pooled red cells to the tube labelled O cells. 
6. Gently mix the contents of the tubes; then centrifuge to 1000rpm for 1 
minute. 
7. Examine the serum overlying the red cell buttons for evidence of hemolysis. 
Gently resuspend the cell buttons, and examine them for agglutination 
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8. Read, interpret, and record test results. Compare serum test results with those 
obtained in testing red cells   
Interpretation 
1. Agglutination of tested red cells and either hemolysis or agglutination in 
tests with serum or plasma constitute positive test results. (Appendix) 
2. A smooth cell suspension after re-suspension of the cell button is a negative 
test result. 
Method 3: Determination of Rh D type (Tube) 
Reagents 
Monoclonal IgM, IgM & IgG (Blend), Test tubes and Centrifuge 
Procedure 
1. Place one drop of Monoclonal IgM in test tubes labelled D1, Positive  
control 1, Negative Control 1. 
2. Place one drop of Monoclonal IgM & IgG (blend) in test tube labelled D2, 
Positive control 2, Negative control 2. 
3. Add one drop 2-5% cell suspension of test cells to test tubes labelled D1 & 
D2. 
4. Add one drop 2-5% cell suspension of known Rh D positive cells to test 
tubes labelled Positive Control 1& 2. 
5. Add one drop 2-5% cell suspension of known Rh D Negative cells to test 
tubes labelled Positive Control 1& 2. 
6. Mix gently and centrifuge at 1000rpm for 1 minute 
7. Gently resuspend the cell button and examine for agglutination. 
8. Grade reaction and record the results (test & control). 
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9. In case of negative reaction incubate IgM & IgG (blend) test tubes at 37˚C 
for 30 minutes. 
10. Confirm the Negative results with weak D/Du testing. 
Interpretation 
1. Agglutination of tested red cells and agglutination in Positive Control 
constitute positive test results. 
2. A smooth cell suspension after re-suspension of the cell button in tested red 
cells and Negative Control and after weak ‘D’ test is a negative test result. 
Method 4: Direct Antiglobulin Testing (DAT) using LISS Coombs’ Gel Card 
Materials: 
LISS Coombs’ Gel Card, Pipette, Tips, Card Holder, ID-Centrifuge. 
Principle 
To detect the presence of IgG and Complement binding antibodies coated on 
patients’ red cells. Cells coated with IgG and/or complement will show agglutination 
with broad spectrum AHG reagent. 
Procedure 
1. Label the Microtube with patient’s name. Remove the Aluminium foil of as 
many Microtubes required by holding the ID card in upright position. 
2. Pipette out 50µl of red cell suspension (0.8-1%) to appropriate Microtubes. 
3. Centrifuge the ID-Card at 910rpm for 10 minutes in the ID-Centrifuge 
4. Read and Record the results.(read the card from both sides). 
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Interpretation 
Positive: Agglutinated cells forming a red line on the surface of the gel or dispersed 
in the column. 
Negative: Compact button of cells settled on the bottom of the Microtube. 
Gel test reactions are graded from 0 to 4+ (Appendix). 
Method 5: Direct Antiglobulin Testing (DAT) using Monospecific Gel Card 
Principle: 
To detect the presence of incomplete antibodies and complement coated on 
patients’ red cells which are IgG, IgM, IgA, C3d, and C3c using Monospecific gel 
card containing Anti IgG, Anti IgM, Anti IgA, Anti C3d and Anti C3c respectively. 
Materials  
1. ID-Monospecific card with 6 columns (Fig2 containing Anti IgG, Anti IgM, 
Anti IgA, Anti C3d, Anti C3c and Negative Control Microtube) 
2. Micro Pipette, Micro Tips, ID-Centrifuge 
Procedure 
1. Label the Monospecific DAT ID-card appropriately with patients’ 
ID/hospital ID No. 
2. Remove the aluminium foil, by holding the card in upright position. 
3. Add 50µl of 0.8% suspension of patients’ red cells suspended in LISS to 
monospecific ID-Card. 
4. Centrifuge the card in ID-Centrifuge at 910rpm for 10minutes. 
5. Read and record the reactions. (Read the reactions on both sides of the card). 
6. If the patients were noted to have IgG antibodies on monospecific DAT, 
Further subtyping of IgG was done. 
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Method 6: IgG1 and IgG3 Subclass Identification 
Principle 
 The risk of hemolysis depends on the amount of IgG coated on the Red cells 
and also on the subclass of the IgG. To induce phagocytosis it is said that 
approximately 1000-4000 IgG1 molecules or 135-500 IgG3 molecules must coat the 
red cells. Therefore it is not only the presence of subclasses and also the estimation 
of titre levels to comprehend clinical significance. 
The ID-Sub Class gel card “DAT IgG1/IgG3” has two Dilutions for both 
classes.  
Materials 
1. Subclass ID-card with 6 Microtubes (fig 3, two Microtubes having 1:1 and 
1:100 dilution for both IgG1 and IgG3 respectively, one Negative Control 
and one Positive Control Microtubes)  
2. Pipettes, Micro Tips, ID-Centrifuge 
Procedure 
1. Label the ID-card (Subclass) with appropriate patient ID/Hospital No. 
2. Remove the aluminium foil, by holding the card in upright position. 
3. Pipette 50µl of 0.8% suspension of patients’ red cells suspended in LISS into 
each Microtube. 
4. Centrifuge the card in ID-Centrifuge at 910rpm for 10minutes. 
5. Read and record the reactions. (Read the reactions on both sides of the card). 
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Interpretation 
A. Positive:  
A positive reaction with the dilution of 1:1 has a sensitivity of approximately 
1000 anti-IgG1 molecules and 125 anti-IgG3 molecules respectively.  
 A positive reaction in 1:100 dilution is indicative of higher strength of 
antibodies coating the RBCs.  
B. Negative:  
Compact button of cells settles at the bottom of Microtube. 
Method 7: Thermal amplitude of autoantibodies 
Materials 
Test tubes, 3% to 5% patient’s red cell suspension, Pipette, tips and 
Centrifuge. 
Procedure 
1. Label three test tubes as 4˚C, 22˚C, 37˚C. 
2. Add 100µl of patient’s serum to be tested to each of the labeled test tubes. 
3. Add 50 µl of patient’s 3% to 5% red cell suspension to each test tube. 
4. Incubate at respective temperature for 30 minutes. 
5. Centrifuge at 1000rpm for 1minute. 
6. Examine each tube for agglutination and record the results. 
7. Wash each tube with normal saline for 3 times. 
8. Add 2 drops of AHG to each test tube and mix. Centrifuge at 1000rpm for 
1minute. Examine each tube for agglutination 
9. If macroscopic agglutination is not observed or if it is equivocal then examine 
microscopically for agglutination. Interpret the results.    
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Method 8: Cold Agglutinin Titer Procedure 
Specimen 
Serum or plasma, separated at 37 C from a sample maintained and/or 
allowed to clot at 37 C, or plasma, separated from an anticoagulated sample after 
periodic inversion at 37 C for approximately 15 minutes. 
Reagents 
1.  A pool of two or more examples of washed group O I adult red cells  
2.  Normal saline (NS), pH 7.3. 
Procedure 
1. Prepare serial twofold dilutions of the patient’s serum or plasma in NS. The 
dilution range should be from 1 in 2 to 1 in 4096 (12 tubes).  
2. Mix 2 drops of each dilution with 1 drop of a 3% to 5% suspension of red cells. 
3. Mix and incubate at 4 C for 1 to 2 hours. 
4. Centrifuge the tubes for 15 to 20 seconds at 900 to 1000 × g, and then place the 
tubes in a rack in an ice water bath. Examine the tubes one by one 
macroscopically for agglutination, starting with the tube at the highest dilution. 
5. Grade and record the results. 
Interpretation  
1. The titer is the reciprocal of the highest serum dilution at which macroscopic 
agglutination is observed.  
2. Titers above 64 are considered elevated, but hemolytic anemia resulting from 
cold-reactive autoagglutinins rarely occurs unless the titer is ≥1000.  
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3. Titers below 1000 may be obtained when the autoantibody has a different 
specificity (eg, anti-i) or if the cold agglutinin is of the less-common low-titer, 
high thermal-amplitude type. 
4. If the patient has a positive direct antiglobulin test (DAT) because of 
complement only and has clinical signs of hemolytic anemia, specificity and 
thermal amplitude studies should be performed. 
Method 9: Elution of DAT positive Red Cells by Glycine acid Method 
Principle 
For identification, the antibody is separated from the red cells by elution 
techniques such as acid elution which is considered most suitable for elution of 
antibodies. 
DiaCidel consists of ready to use reagents offers an easy working procedures 
for the elution of most common antibodies. 
Materials 
1. Concentrated wash solution containing Glycine-NaCl buffer 
2. Elution solution containing a low pH glycine buffer with colour indicator. 
3. Buffer solution containing Tris buffer with bovine albumin (1.2%) 
4. Test tubes, Tube rack, Micro pipette, Micro tips 
5. ID coombs’ card, Antibody screening and identification Reagent Cells 
6.  ID-Incubator, ID-Centrifuge 
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Procedure 
Preparation of the working solution 
Dilute the concentrated wash solution to 1:10 dilution in distilled water 
(1part concentrate + 9 parts of distilled water). 
Stability of the working solution 
The working solution can be stored in a closed bottle for 6 months at 2-8˚C. 
Elution 
1. Wash the red cells which have given a positive DAT once with isotonic saline 
solution. (approximately 1ml of packed cells needed) 
2. Wash 1.0ml of packed red cells 4 times with DiaCidel working wash solution. 
3. Decant completely after last wash and keep part of supernatant to test for the 
presence of irregular antibodies 
4. Add 1.0 ml of DiaCidel elution solution to 1.0 ml washed red cells. 
5. Centrifuge immediately for 1 minute at 3000rpm (900g). 
6. Transfer eluate into a clean test tube. 
7. Add 5 drops of DiaCidel buffer solution to the eluate and mix well. Observe the 
formation of a blue colour, indicating that neutral pH 6.5-7.5 is reached. 
8. Centrifuge the eluate for 1 minute at 3000rpm (900g) to completely remove any 
residual cells. 
9. Eluate is ready for further testing like IAT, Antibody screening and 
Identification. 
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Method 10: Elution by glycine acid EDTA method 
Principle 
Acid glycine/EDTA can be used to dissociate antibody molecules from red 
cell membranes. The procedure is routinely used for blood typing tests or adsorption 
procedures. All common red cell antigens can be detected after treatment with acid 
glycine/EDTA except antigens of the Kell system, Bg antigens, and Er antigens. 
Thus, red cells treated in this manner cannot be used to determine these phenotypes. 
Specimen 
Red cells giving a positive direct antiglobulin test (DAT) result. 
Reagents 
Solution 1: A concentrated solution of sodium EDTA. 0.1% sodium azide as a 
preservative. 
Solution 2: A low-pH glycine. This solution contains no preservative. 
Solution 3: A TRIS hydroxymethyl-aminomethane solution. 0.1% sodium azide as a 
preservative. 
Procedure  
 Wash the red cells to be treated three times with isotonic saline and 
resuspend them into 3-5% concentration. 
 Place 30 drops of washed red cells in a clean test tube. 
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 Centrifuge to pack the red blood cells as completely as possible and carefully 
remove the supernatant without disturbing the red blood cells. 3400 rpm for 
1 minute should pack the red blood cells sufficiently. 
 In a separate test tube, prepare the EDTA glycine-acid solution by adding 4 
drops EGA solution 1 into 16 drops of EGA solution 2. 
 Immediately add the freshly prepared EDTA glycine-acid solution to washed 
packed red blood cells and mix gently. 
 Start a timer and allow the mixture to stand at room temperature for no more 
than 2 minutes. If the red blood cells are markedly tanned or clumped, the 
treatment need to be shortened in 15 second increments until a level achieved 
that do not result in markedly tanning or clumping of red blood cells. 
 Immediately add 4 drops of EGA solution 3(1.0 M TRIS-NaCl), and mix the 
contents of the tube. 
 Centrifuge at 3400 rpm for 30 seconds; then aspirate and discard the 
supernatant fluid. 
 The treated red blood cells are not markedly tanned or clumped. Wash the 
red cells at least three times with normal saline. 
 Test the washed red cells with anti-IgG. If nonreactive with anti-IgG, the 
cells are ready for use in blood typing or adsorption procedures. If the DAT 
is still positive, one additional treatment can be performed. 
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Method 11: Autoadsorption 
Principle  
Antibodies can be removed from a serum sample by adsorption. It may be 
possible to harvest bound antibody by elution or examination of the absorbed serum 
for antibody(ies) remaining after the adsorption process. 
Specimen  
Serum / plasma having antibody to be adsorbed. 
Reagents  
Red cells (Glycine acid/EDTA treated autologous) were used for 
Autoadsorption 
Procedure  
 Wash the selected red cells at least three times with saline. 
 After the last wash, centrifuge the red cells at 800 to 1000 × g for at least 5 
minutes, and remove as much of the supernatant saline as possible. 
Additional saline may be removed by touching the red cell mass with a 
narrow piece of filter paper. 
 Combine appropriate volumes of the packed red cells and serum, and 
incubate at the desired temperature for 30 to 60 minutes. 
 Mix the serum or cell mixture periodically throughout the incubation phase. 
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 Centrifuge the red cells at 800 to 1000 × g for 5 minutes to pack cells tightly. 
Centrifuge at the incubation temperature, if possible, to avoid dissociation of 
antibody from the red cell membranes. 
 Transfer the supernatant fluid, which is the adsorbed serum, to a clean test 
tube. If an eluate is to be prepared, save the red cells. 
 Test an aliquot of the adsorbed serum, preferably against a reserved unused 
aliquot of the red cells used for adsorption, to see if all antibody has been 
removed. 
Interpretation 
If reactivity remains, the antibody has not been completely removed. No 
reactivity signifies that antibody has been completely adsorbed. 
Notes  
1.  Adsorption is more effective if the area of contact between the red cells and 
serum is large. Use of a large-bore test tube (13 mm or larger) is 
recommended. 
2. Multiple adsorptions may be necessary to remove an antibody completely; 
however, each successive adsorption increases the likelihood that the serum 
will be diluted and unadsorbed antibodies weakened. 
3. Repeat adsorptions should use a fresh aliquot of red cells and not the red 
cells from the earlier adsorption. 
4. Enzyme pretreatment of adsorbing red cells can be performed to increase 
antibody uptake for enzyme-resistant antigens. 
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Method 12: Determining the Specificity of Cold-Reactive Autoagglutinins 
Principle 
Cold-reactive autoagglutinins are usually IgM, which binds to red cells in the 
lower temperature of the peripheral circulation and causes complement components 
to attach to the red cells. As the red cells circulate to warmer areas, the IgM 
dissociates but the complement remains. 
Specimens: 
1. Serum or plasma, separated at 37 C from a blood sample maintained and/or 
allowed to clot at 37 C, or plasma, separated from an anticoagulated sample 
after periodic inversion at 37 C for approximately 15 minutes.  
2. Test red cells of the following phenotypes  
1. A pool of two or more examples of adult group O I adult red cells;  
2. Group O i cord red cells.  
3. The patient’s own (autologous) red cells, washed at least three times with 
37 C saline.  
4. Red cells of the same ABO group as the patient, if the patient is not group 
O. If the patient is group A or AB, use both A1 and A2 cells.  
5. Saline 
Procedure 
 Prepare serial twofold dilutions of the serum or plasma in saline. The dilution 
range should be from 1 in 2 to 1 in 4096 (12 tubes), and the volumes prepared 
should be more than the total volume needed to test all of the desired red 
cells. For example, diluting 0.4 mL of serum with 0.4 mL of saline would be 
sufficient to test three red cell examples. 
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 Label a set of 12 tubes with the dilution (eg, 2, 4, 8, etc) for each kind of red 
cells to be tested (eg, adult, cord, autologous). 
 Dispense 2 drops of each dilution into the appropriate tubes. 
 Add 1 drop of a 3% to 5% saline suspension of each red cell sample to the 
appropriate set of tubes. 
 Mix and incubate at room temperature for 30 to 60 minutes. 
 Centrifuge for 15 to 20 seconds at 900 to 1000 × g. Examine the tubes for 
agglutination, starting with the set of tubes at the highest dilution for each cell 
tested (ie, read all the tubes for each dilution as a set). Grade and record the 
results.  
 Incubate the tubes at 4˚ C for 1 to 2 hours. 
 Centrifuge for 15 to 20 seconds at 900 to 1000 × g. Immediately place the 
tubes in a rack in an ice water bath. Examine the tubes as in step 6. Grade and 
record the results. 
Interpretation 
Red Cells 
Antibody Specificity 
Anti-I Anti-i Anti-I
T 
Anti-IH Anti-Pr 
O I Adult + - 0/↓ + + 
O i Cord - + 0/↓ ↓ + 
Autologous + 0/↓ 0/↓ ↓ + 
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RESULTS 
 
Total of 57 cases of DAT positive samples were included in the study during 
the study period from August 2017 to September 2018. 
On analysing the cause of DAT positivity the patients belonged to different 
categories. The patients were belonged to  
 Autoimmune Hemolytic Anemia,  
 Hemolytic Diseases of Fetus and Newborn and  
 Delayed Hemolytic Transfusion Reaction  
All these patients were included in the study, since the distributions of these 
cases were presented with features of hemolysis and Direct Anti Globulin Test 
positivity. 
Distribution of DAT positive cases 
AIHA 34, HDFN 21, DHTR 2 
 
AIHA 
60% 
HDFN 
37% 
DHTR 
3% 
Distribution of DAT Positive cases 
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Autoimmune hemolytic anemia 
Out of 34 AIHA patients 25 patients were found to have WAIHA, 6 had 
CAS and 3 had mixed type of AIHA. 
Type of AIHA 
Out of 34 patients, 20 (59%) patients were diagnosed to have primary AIHA 
and the remaining 14 (41%) patients had secondary AIHA. 
Causes of secondary AIHA are, 
1. Autoimmune Disorders (SLE=4; RA=1) 
2. Lymphoproliferative disorders (n=3) 
3. Infections (n=1) 
4. Sickle cell anemia(n=2) 
5. Ovarian tumours(n=2) and  
6. Cancer cervix (n=1) 
Age Distribution of AIHA Patients 
The age distribution of AIHA patients ranged from 3 years to 79 years with a 
median age of 38 years. 
 
15% 
32% 
53% 
Age distribution of AIHA patients 
˂15 years 
16-40 years
˃41 years 
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32% 
68% 
Gender distribution of AIHA patients 
Male Female
˂15 years 16-40 years  ˃41 years 
2 
7 
11 
3 
5 
6 
Age Distribution of patients in primary and secondary 
AIHA 
Primary Secondary
Age Distribution of Patients in primary and secondary AIHA 
When comparing the age distribution of between primary and secondary 
AIHA, median age was 40 years in primary (Range 3-79years) and 26 years in 
secondary AIHA (Range 5-70 years). Primary AIHA was most predominantly seen 
in ˃41 years of age (58%) and Secondary AIHA was more common among < 30 
years of age (57%). 
 
 
 
 
 
 
 
Gender distribution 
In our study of 34 AIHA patients, 11 (33%) were males and 23(67%) were 
females with overall ratio of 1:2 (11:23)  
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Gender distribution in primary and secondary AIHA 
While comparing the gender distribution among primary and secondary 
AIHA patients, Male to Female ratio was noted to be 1:2.2 in primary AIHA and 
1:1.8 for secondary AIHA. 
 
Severity of AIHA 
Hemolysis was classified into Severe, Moderate based on study criteria laid 
down by Wheeler et al and Das ss et al. out of 34 AIHA patients, 20 (59%) patients 
were belonged to severe hemolysis, 14(41%) patients had moderate hemolysis as 
shown in the picture below.
77,14 
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Severity of hemolysis in primary and secondary AIHA patients 
Among 20 AIHA patients with severe hemolysis, 12 had primary AIHA and 
8 had secondary AIHA. The association of primary AIHA with severe Hemolysis 
found to be statistically significant with p ˂0.006 (OR=13.5, 95% CI 2.15-84.70). 
Moderate hemolysis was common among secondary AIHA patients. 
 
HGB and Bilirubin values in primary and secondary AIHA patients 
Hemoglobin and Bilirubin were assessed in AIHA patients with severe and 
moderate hemolysis by unpaired T test. There is statistically significant difference in 
mean hemoglobin in patients with severe and moderate hemolysis. The mean 
hemoglobin of severe hemolysis is 5.6gm/dl and of moderate hemolysis is 8.2gm/dl. 
(p ˂0.0001). 
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71% 
29% 
Distribution of strength of DAT 
>2+ <2+
Reticulocytes and LDH values in severe and moderate hemolysis 
Values of Reticulocytes and LDH Values were assessed in AIHA patients 
with severe and moderate hemolysis by Mann Whitney test and they are statistically 
significant with a p value of ˂0.001. 
  
Immunohematological Parameters 
Distribution of polyspecific DAT positivity among AIHA patients 
Out of 34 AIHA patients, 24 (71%) patients were having DAT strength of 
>2+ and remaining 10 (29%) patients had DAT strength of <2+. 
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The strength of polyspecific DAT with severity of hemolysis  
 We found that Among 24 AIHA patients with >2+ DAT strength 18 (75%) 
of had severe hemolysis, but only 2 (10%) out of 10 AIHA patients with <2+ DAT 
strength had severe hemolysis. The chi-square test showed that the patients with 
DAT strength more than 2+ were more likely to have severe hemolysis compared to 
patients having 2+ or less DAT reactions. This correlation was statistically 
significant with a p value of < 0.003.  
 
Distribution of autoantibodies in AIHA 
 Among the 34 patients of AIHA, multiple antibodies (ie; IgG with other 
antibodies or complement) were found in 17 (50%) patients, IgG alone was found in 
11 (32%) patients and C3d alone was identified in 6 (18%) of AIHA patients. 
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The various combinations of Autoantibodies (Monospecific DAT) in the study 
population 
Autoantibody Combinations 
Severe Moderate 
N=20 N=14 
IgG only 3 8 
IgG & C3d 11 1 
IgG & IgA 2 0 
IgG, IgM & C3d 1 0 
IgG, IgM, IgA &C3d 2 0 
C3d only 1 5 
 
Comparison of IgG only and IgG with multiple Antibodies with or without 
complement 
Among 20 AIHA patients with severe hemolysis, 16 (80%) had combination 
of antibodies in comparison to 3 (15%) patients who had solitary IgG antibody. 1 
(5%) severe hemolysis patient was having only C3d. The severity of hemolysis is 
statistically significant in AIHA patients having autoantibodies (IgG with 
combination) with a p value of 0.002. 
Distribution of IgG subtypes 
Out of 28 patients with IgG, 11 of them had solitary IgG antibody and 17 of 
them had IgG with combination of other autoantibodies. IgG1 was the most 
common subtype present in 11 (40%) patients, followed by IgG1 and IgG3 which 
was present in 8 (29%) patients and solitary IgG3 was found in 4 (14%) patients 
with AIHA. In our study 5 (17%) patients had neither IgG1 nor IgG3. 
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Correlation of IgG subtypes with severity of hemolysis 
 The presence of both IgG1 and IgG3 has a significant effect on severity of 
hemolysis. A total of 8 patients were noted to have both IgG1 and IgG3 in which 7 
(87%) had severe hemolysis in par with 1 (13%) moderate hemolysis. A similar 
impact was noted in patients with solitary IgG1 [95% CI= 25.0570 to 88.9932; P = 
0.0042]. Among 11 AIHA patients with only IgG1 autoantibody 10 (90%) had 
severe hemolysis and 1 (10%) 95% [CI= 39.2760 to 91.4404; P = 0.0002] were 
having moderate hemolysis. Both of these associations were statistically 
significant. 
 Among 4 AIHA patients who had IgG3 subclass, 3(75%) had moderate 
hemolysis and 1 (25%) had severe hemolysis. In 5 AIHA patients who had neither 
IgG1 nor IgG3, 4 (80%) had moderate hemolysis and 1 (10%) had severe hemolysis. 
Correlation of IgG subtypes with combination of other autoantibodies 
  IgG subtypes in combination with other antibodies and/or complement was 
found in 17 AIHA patients. 
IgG subtypes with other 
Antibodies 
moderate severe total p value 
IgG1 0 10 10 
0.126 
IgG1 and IgG3 1 4 5 
 
IgG1
IgG1 & IgG3
IgG3
Neither IgG1 nor IgG3
40% 
29% 
14% 
17% 
Distribution of IgG subtypes in AIHA 
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I group of 10 AIHA patients were noted to have IgG1 in combination with 
other autoantibodies and/or complement. All of them had severe hemolysis. 
II group of 5 AIHA patients who had IgG1 and IgG3 in combination with 
other autoantibodies and/or complement, 4 had severe hemolysis in comparison to 1 
patient with moderate hemolysis. Logistic analysis showed the patients with severe 
hemolysis were associated with the presence of both IgG1 alone and IgG1 with 
IgG3, however this is not statistically significant. 
The association of IgG subclass in combination with other autoantibodies 
and/or complement to severe hemolysis was not statistically significant among the 
study population. 
Correlation of complement fixation in AIHA patients with IgG1 and/or IgG3 
subclass 
Among AIHA patients the impact of complement fixation with IgG1 and/or 
IgG3 subclass were studied. In the study population, 11 patients were having IgG1 
and/or IgG3 without complement fixation as compared to 13 patients who had 
complement fixation.  
 moderate Severe Total p value 
IgG1 &/ IgG3 8 3 11 
0.000 
IgG1 &/ IgG3 with complement 1 14 15 
 
This association between IgG1 and/or IgG3 and complement fixation is 
statistically significant with a p value of 0.000. 
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Distribution of Auto and Alloantibody among AIHA patients 
Out of 34 AIHA patients 30 (88%) had autoantibodies and 4 (12%) patients 
had both auto and alloantibodies. 
 
Thermal Amplitude of auto antibodies 
Out of 34 AIHA patients, 25 warm autoantibodies reacted at 37˚C, among 6 
Cold AIHA 3 had thermal amplitude of 4˚C to 22˚C and 3 had wide thermal 
amplitude of 4˚C to 37˚C. In 3 Mixed AIHA cold autoantibodies had thermal 
amplitude of 4˚C to 22˚C and warm autoantibodies reacted at 37˚C. 
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Autoantibodies
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Acid Elution in AIHA patients 
 Among the 34 DAT positive samples, Elution was done in all AIHA 
patients, who had IgG autoantibody alone, IgG with other autoantibodies and/or 
complement and complement alone. Out of 34 elutions, 28(82%) samples were 
reactive with RBC reagent panel and 6 (18%) samples were nonreactive with the 
same.  
 
All the reactive eluates belonged to either warm or mixed AIHA patients and 
the nonreactive eluates belonged to patients with CAS.  
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 Among 28 reactive eluates 22 were showing panagglutination, in which 21 
(73%) were WAIHA with, 1 (4%) was due to mixed AIHA and 6 (23%) AIHA 
samples showed the presence of autoantibody specificity as anti-e which was 
confirmed with serum studies (4 were due to WAIHA and 2 were mixed AIHA). 
Elution with Glycine Acid EDTA 
Among 34 patients with AIHA Glycine Acid EDTA was carried out in 
patients who are diagnosed case of AIHA and in patients with h/o previous 
transfusion more than 3 months. This implies that Glycine acid EDTA was done in 
29 patients of AIHA and test is not done in 3 cases of CAS (thermal amplitude of 
4˚C to 22˚C) and 2 patients with a recent history of transfusion( < 7days). 
 
 Glycine Acid EDTA rendered 18 samples of DAT completely negative and 
in the remaining 11 AIHA cases the strength of DAT is reduced than its original 
strength.  
Autoadsorption 
 Among 28 AIHA patients, 7 patients whom had previous history of blood 
transfusions. The strength of IAT and DAT were correlated to rule out the presence 
of alloantibody. The Autoadsorption was done in 5 AIHA patients with a history of 
Gly acid/EDTA
85% 
15% 
Glycine Acid EDTA  
Test done not done
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blood transfusions more than 3 months and having IAT strength more than or equal 
to the strength of DAT. The Autoadsorption revealed the presence of clinically 
significant alloantibodies in 4 out of 5 patients and one patient was having AIHA 
only. (Autoadsorption done after treating the DAT positive autologous red cells with 
glycine acid EDTA and rendering them DAT negative).  
Identified autoantibodies and alloantibodies by elution and/or absorption and 
elution 
Out 24 AIHA patients with only autoantibodies 18 (55%) had panagglutination and 
6 AIHA patients were found to have specificity against Rh antigen (anti-e).  
6 Cold AIHA patients with specificity against I antigen (anti-I) 1 had severe 
haemolysis; in 5 patients there was moderate haemolysis.  
 
Alloantibodies were identified in 4/20 (20%) in relation to AIHA patients 
with severe hemolysis and all of them had previous history of transfusion. 3 of 4 
patients had single clinically significant alloantibody and 1 of 4 had multiple 
clinically significant alloantibodies. The association between transfusion and 
alloantibody formation is statistically significant with a p value of 0.000.   
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Auto and Alloantibodies vs hemolysis 
 Severe hemolysis Moderate hemolysis 
Autoantibodies with 
Panagglutination 
11/20 8/13 
Autoantibodies with 
Specificity 
Anti-e (4/6) 
Anti-I (1/6) 
Anti-e (2/6) 
Anti-I (5/6) 
Autoantibodies with 
Alloantibodies 
Anti-C, Anti-c, 
Anti-E, Anti-Jka,s,Fya 
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II. Hemolytic Diseases of Fetus and New-born (HDFN)  
II. 1: Etiology 
 Out of 21 cases of DAT positive HDFN cases received 17 were due to Rh, 3 
were due to ABO HDFN and 1 is due to others (Anti-M).  
 
II. 2: Correlation of Hyperbilirubinemia (TSB >15mg/dl) with HDFN 
From a total of 21neonates, 16 (76%) have with hyperbilirubinemia TSB 
>15mg/dl, in which 5 infants needed ET and 11 were treated with phototherapy. The 
remaining 5 Infants who had mild hyperbilirubinemia TSB < 15mg/dl needed no 
intervention.  
There is statistically significant correlation between hyperbilirubinemia 
with the management of HDFN and has a p value of < 0.000. (Mann-Whitney 
test / Two-tailed test) 
81% 
14% 
5% 
Etiology of HDFN 
Rh system
ABO
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Correlation of HGB with severity of HDFN 
Hemoglobin was assessed in patients with moderate to severe HDFN and 
mild HDFN by unpaired T test. The mean hemoglobin of moderate to severe 
hemolysis is 13.46gm/dl and of mild HDFN is 16.04gm/dl.  
There is statistically significant Correlation in hemoglobin between 
patients with moderate to severe hemolysis and mild hemolysis (p ˂0.0013). 
               
II. 3:  Correlation between Strength of DAT with severity of HDFN 
Out of 16 neonates with Moderate to severe HDFN 15 neonates had >2+ 
DAT strength and 1 neonates had <2+as strength of DAT and among 5 neonates 
having<2+ as strength of DAT, 4 of them presented with mild HDFN had 1 neonates 
were having Moderate to severe HDFN. 
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There is a statistically significant Correlation between Strength of DAT with 
severity of HDFN with a p value of 0.012. 
II.5: Specificity of DAT in HDFN 
 Out of 21 cases of HDFN (100%) all of them had anti-IgG only in 
Monospecific DAT.  
II. 6: Distribution of IgG subtypes 
Out of 21 HDFN cases, IgG1 was identified in 12 neonates; IgG1 & IgG3, 
IgG3 and neither IgG1 nor IgG3 were seen in 3 neonates in each group. 
Distribution of IgG subtypes 
 
IgG Subtypes 
Moderate to 
severe HDFN 
Mild HDFN Total 
N=16 N=5 N=21 
IgG1 10 2 11 
IgG1 & IgG3 3 0 6 
IgG3 1 2 3 
Neither IgG1 nor IgG3 2 1 1 
 
II. 7: Correlation of IgG subclass with severity 
 Among 21 neonates with HDFN, 11 had IgG1 (9 moderate to severe and 2 
mild HDFN); 6 neonates had IgG1 & IgG3 subtypes all of them had Moderate to 
severe HDFN, 3 neonates were having IgG3 subtype in which 2 had severe HDFN 
and 1 had mild HDFN; finally in the group of neither IgG1 nor IgG3 1 neonate had 
mild HDFN. 
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IgG Subtypes Mild Moderate to severe 
IgG1, IgG1 & IgG3 2 15 
IgG3, Neither IgG1 nor IgG3 3 1 
 
 There is a statistically significant correlation between the presence of 
IgG1, IgG1 and IgG3 antibodies and moderate to severe HDFN with a p value 
of < 0.012 
II. 9: Correlation of hemolysis with Rh HDFN and ABO HDFN 
 Out of 17 Rh HDFN neonates, 15 had moderate to severe HDFN and 2 had 
mild HDFN. Out 3 ABO HDFN neonates in this present study 1(33%) neonate had 
moderate to severe HDFN and 2 (67%) neonates had mild HDFN. 
 
However, there is significant correlation between Rh HDFN and severity 
of hemolysis with a p value of 0.012. 
II. 10: Acid Elution in HDFN 
Among the 21 neonates acid elution was done in all the infants. 20 eluates 
were reactive and 1 eluate of ABO HDFN was nonreactive. 
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 In this study there is a statistically significant correlation between the 
DAT positive neonates and antibody identification in the eluate with a p value 
of <0.0001. 
Glycine Acid EDTA Elution in HDFN 
 Out of 21 HDFN neonates all under gone Glycine Acid EDTA DAT was 
negative in and Rh phenotyping along with other specific phenotypes were 
identified. However, Kell antigens (K,k) were destroyed by this elution method. 
Probable Phenotype No. of neonates 
D, C, c, e,  10 
D, C, c, E, e 01 
D, c, e 04 
D, c, E, e,  02 
D, C, c, e, M, N, s  01   
D, c, E, e, A 01 
D, C, c, e, A 01 
D, C, c, e, B 01 
 
 
 
Rh HDFN 
81% 
ABO HDFN 
9% 
Others 
5% 
unidentified 
5% 
Antibody identification by glycine acid 
elution 
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Antibodies found in neonates with HDFN 
Out of 17 Rh HDFN neonates Anti-D was found in 13 (76%) neonates, anti-
D & anti-C was found in 2 (12%) neonates, anti-c was found in 2 (12%) neonates 
only. Among 3 ABO HDFN Anti-A was found in 1 Neonate and Anti-B was found 
in 1 neonate and among other blood group antigens anti-M was found in 1 neonate.  
 
 
III. Delayed hemolytic / serological transfusion reaction 
III. A. The strength of polyspecific DAT in DHTR 
 Out of 2 cases 1 had 2+ in polyspecific DAT and 1 had 1+ reaction in 
polyspecific DAT. 
III. B. Features Of Hemolysis  
 HGB gm/dl TSB mg/dl LDH IU/ml Retic 
Patient 1 6.3 2.8 615 4% 
Patient 2 7.4 2.4 532 2% 
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III. C. Distribution of antibodies by monospecific DAT 
Out of 2 cases of delayed hemolytic transfusion reactions both of them had 
IgG and C3d in their coated RBCs identified by monospecific DAT.  
III. D. Distribution of IgG subtypes 
 Both patients of delayed hemolytic transfusion reactions had IgG1 subclass 
which was identified by IgG subclass card. 
IV. E. Elution in DHTR 
In Acid elution of both DAT positive DHTR samples we found the presence 
of Anti-Jk
a
 and anti-c both are clinically significant antibodies. However Anti-c was 
identified in 1 patient’s serum also. 
Glycine Acid EDTA Elution   
Glycine Acid EDTA Elution was not performed in both the DHTR patients 
since they had h/o transfusion 6 days and 10 days back respectively.  
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Elution of DAT positive samples in overall view 
 Table 1: Comparison of antibodies in serum and Eluate 
Antibody(-ies) Number % of Total 
A. In serum   
Alloantibody 19 
[17 Rh HDFN, 1 other(Anti-M 
HDFN) & 1 DHTR] 
33.33% 
Warm autoantibody 08 
(6 anti-e & 2 panagglutinins) 
14.03% 
Warm autoantibody plus 
Alloantibody 
04 
( DAT & AC +ve and h/o tx 
present > 3months) 
7.02% 
Cold and Mixed Autoantibody 06 
(3 CAS + 3 mixed AIHA) 
10.54% 
No antibodies (antibody 
detection test negative in 
serum) 
20 
(16 AIHA, 3 HDFN & 1 DHTR) 
35.08% 
Total 57 100% 
B. Elute   
Alloantibody 20 
[17 Rh HDFN, 1 other(Anti-M 
HDFN) & 2 DHTR] 
35.1% 
Warm autoantibody 21 
(6 anti-e & 15 Panagglutinins) 
36.8% 
Nonreactive 07 
(6 CAS & 1 ABO HDFN) 
12.2% 
Cold and Mixed Autoantibody 03 
(All 3 Mixed AIHA) 
5.3% 
Anti-A or anti-B 02 
(1anti-A & 1 anti-B) 
3.5% 
Warm autoantibody plus 
Alloantibody 
04 
[1 anti-c,1 anti-C, 1anti-E & 
1(anti- Fy
a
 &anti-S)] 
7.1% 
Total 57 100% 
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A total of 57 eluates were analysed during the study period. In Table 1A 
demonstrates the type of antibodies present in the serum of the study population at 
the time of elution performed. The type of antibodies recovered in the eluate shown 
in the table 1B. There was a total of 20 non anti-A/B alloantibodies were recovered 
from 57 eluates. In which 17 antibodies were against Rh antigens, 2 were due DHTR 
and 1 in the group of HDFN due to other antigens. Among the 21 warm 
autoantibodies 6 were having Autoanti-e specificity and remaining 15 were 
panagglutinating autoantibodies. Anti-A/B alloantibodies were eluted from 2 out of 
3 ABO HDFN neonates and 1 of this eluate was nonreactive. 
Characteristics of the DAT strengths and the informative eluates in this study 
Table 2 shows the strength of antecedent DATs along with the resultant 
informative eluates was elaborated in the above said Table 2.  In total there were 50 
informative eluates from 57 DAT positive cases. In which, 28 belonged to AIHA 
(25 wAIHA and 3 mixed AIHA), 17 belonged to Rh HDFN,3 belonged to ABO & 
Anti-M HDFN and 2 belonged to DHTR. In which 16 out of 57 eluates were 
informative for an antibody which was not detected in the serum at the time elution 
performed constituting 28% of the total study population. The all informative eluates 
found in patients having IgG antibody with and /or without the presence of other 
antibodies. (13 cases of AIHA, 2 cases of ABO HDFN and 1 case of DHTR). 
Among the 16 informative eluates, 13 eluates were causing panagglutination 
(recovered antibody caused agglutination of all reagent RBCs). 2 were informative 
eluates of ABO HDFN 1 belonged to anti-A and 1 had anti-B specificity. In the 
DHTR group 1 informative eluate showed the specificity of anti-Jka. 
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Table 2: Characteristics of the DAT strengths and the informative eluates in this study 
DAT 
strength 
Total 
number 
of elutes 
n=57 
Total 
number of 
informative 
elutes n=50 
No of 
Panagglutinating 
Abs/ anti-e 
specificity  in 
serum n=15 
No of 
Panagglutinating 
Abs in elute only 
No of Rh 
HDFN Abs 
in serum 
No of 
informative 
eluates in 
Rh HDFN 
No of 
ABO & 
others 
HDFN 
Abs in 
Serum 
No of 
informative 
eluates in 
ABO HDFN 
& others 
No of 
DHTR 
Abs in 
serum 
No of 
informative 
eluates in 
DHTR 
1+ 1 1 - -    - - 1 antiJk
a 
2+ 13 6 1 (auto with 
Alloab*) 
3 1 1 - - 1 
anti-c 
1 anti-c 
3+ 17 17 2 (1 auto & 1 auto 
with alloab*) 
4 8 8 1 (anti-M 
HDFN) 
3 (2 ABO & 
anti-M HDFN) 
- - 
4+ 26 26 12 (anti-e 6, 4 
panagg & 2 auto 
with alloabs*) 
6 7*(maternal 
serum not 
available) 
8 - - - - 
Total 57 50 15 13 16 17 1 3 1 2 
 
*alloantibody was diagnosed in Autoadsorbed serum. 
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Glycine Acid EDTA Elution  
         Among 57 patients with DAT positivity Glycine Acid EDTA was carried out 
in 50 DAT positive patients who are diagnosed to have AIHA and HDFN. This 
implies that Glycine acid EDTA was not done 3 cases of CAS, 2 AIHA patients with 
a recent history of transfusion (< 7days) and also in 2 cases of DHTR. Glycine Acid 
EDTA rendered 39 samples (18 AIHA and 21 HDFN) of DAT completely negative 
and in the remaining 11 (AIHA)cases the strength of DAT is very much reduced 
than its original strength. 
Type of antibodies recovered in Autoadsorbed eluates and compared with those 
patients' Autoadsorbed sera 
5 AIHA patients with a previous history of transfusion and having increased 
IAT strength subjected to Autoadsorption. RBC coated autoantibodies were 
removed by Glycine Acid EDTA and the treated RBCs are used for Autoadsorption. 
Table 4: Alloantibody in AIHA 
Pt Id 
No 
Antibody Screening in 
Serum 
Antibody Screening After 
Autoadsorption 
In Eluate In Serum 
A 4 Panagglutinins Panagglutinins anti-C 
A 14 Panagglutinins Panagglutinins anti-fya,S 
A 18 Panagglutinins Panagglutinins anti-E 
A 24 Panagglutinins Panagglutinins anti-c 
A 31 Panagglutinins Panagglutinins Negative 
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DISCUSSION 
 
The DAT is widely used in Immunohematological laboratory test because it 
is simple, quick and inexpensive test. It should be performed when the presence of 
haemolysis has been established and is one of the most important diagnostic tests for 
determining Immune Hemolytic Anemias. In view of this, it is very essential to 
identify the patients with DAT positive and also having hemolysis to aid in the 
treatment and management accordingly to the specific cause of DAT positivity. 
With this background this study was conducted, to evaluate the DAT positive cases 
and to characterise them into AIHA, HDFN, HTR and/or other causes along with the 
various factors, antibody classes, severity and finally to perform elution studies to 
specify the antibody coated onto the red cells. 
I. Autoimmune hemolytic anemia (AIHA) is a rare disease characterised by 
the production of autoantibodies against one’s own red cell antigens. The degree of 
hemolysis depends upon the following factors such as Immunoglobulin class, 
subclass, titre, ability to activate complement, thermal amplitude and strength of 
direct antiglobulin test (DAT) 
41 
Accurate diagnosis of autoimmune hemolytic 
anemia is mandatory, as the condition requires different strategies for therapy and 
monitoring. Therefore awareness of demographics, clinical presentation, laboratory 
and serological tests is required for diagnosis of AIHAs.
6 
This present study includes 34 AIHA patients based on the features of 
hemolysis and Direct Antiglobulin Test positivity. 
It is well known that AIHA is most common among females than males. 
Similar trend was noted in our study population with a male: female ratio of 1:2 
(11:23) ie 67% of idiopathic AIHA patients were females. The gender distribution 
85 
 
among primary and secondary AIHA patients was noted to be 1:2.2 in primary 
AIHA and 1:1.8 for secondary AIHA.  
 Similarly, Allgood and Chaplin in their study reported that 60% of patients 
were female
48
 Dacie reported 58% of patients were female.
50
 Böttiger and 
Westerholm reported that women predominated in all age groups with the exception 
of the youngest (0 to 14 years), in which the sex distribution was even. In secondary 
WAIHA, the percentages are more varied, perhaps depending on the incidence of 
underlying diseases seen in referral centers.
 51
 
Out of 34 patients, 19 (56%) patients were diagnosed to have primary AIHA 
and the remaining 14 (44%) patients had secondary AIHA. This finding is in 
accordance to Naithani et al., they found out that frequency of primary AIHA is 65% 
and that of secondary AIHA is 35%.
26
 In the study by Sokol et al Idiopathic/Primary 
AIHA accounts for 40.9% of all WAIHA.
37
 Warm AIHA is the subtype that most 
often affects children age between 2–12 years.39 
In this study group, the minimum age for presentation was 3 years and the 
maximum age was 79 years. The median age was 40 years in primary (Range 3-
79years) and 26 years in secondary AIHA (Range 5-54years). Primary AIHA was 
most predominantly seen in ˃41 years of age (58%) and Secondary AIHA was more 
common among ˂45 years of age (60%). 
The most common cause for secondary AIHA was Autoimmune disorders 
(SLE and Rheumatoid Arthritis) and followed by sickle cell anemia and 
lymphoproliferative disorders. This finding is reflected in the younger age of 
presentation of secondary AIHA.
125 
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The degree of hemolysis in our study population was evaluated based on the 
following four parameters viz., Hemoglobin <9gm/dl, Bilirubin >2mg/dl, Lactate 
dehydrogenase 500IU/ml and Reticulocyte count >2%.
14,78,144
  
Based on these parameters the hemolysis is classified into moderate, severe 
hemolysis. In our study 20(59%) patients had severe hemolysis, 13(41%) AIHA 
patients had moderate hemolysis. SS Das et al in their study classified hemolysis 
among AIHA patients into two groups only and they observed that 39.53% had 
severe hemolysis and 60.47% had moderate hemolysis.
14 
Correlation of strength of Polyspecific DAT with severity of hemolysis 
The strength of DAT positivity correlates with the number of 
Immunoglobulin molecules adherent to RBC. To assess the strength of DAT various 
techniques have been performed viz, tube technique, CAT, flow cytometry etc. In 
literature many studies have been done to assess the correlation of strength of 
Polyspecific DAT with severity of hemolysis. In our study, polyspecific DAT, 
Monospecific DAT and IgG subtype was done by CAT technique.  
In the present study of 34 patients with AIHA 24 patients had the DAT 
strength of >2+ and remaining 10 patients had <2+ DAT strength. Correlating the 
strength of the DAT with the severity of hemolysis, we found that Among 24 AIHA 
patients with >2+ DAT strength, 18 (75%) of had severe hemolysis, but only 2 
(10%) out of 10 AIHA patients with <2+ DAT strength had severe hemolysis. This 
correlation was statistically significant with a p value of < 0.003. Similarly Wheeler 
et al., in their study found out that the relationship between the presences or absence 
of hemolysis and the DAT strength was highly statistically significant.
78
 Wikman in 
his study revealed that there was a significant correlation between strength of DAT 
and severe hemolysis.
77 
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Autoantibodies in AIHA 
In our study we found that among the 28 AIHA patients with IgG antibodies, 
IgG with other antibodies or complement were found in 50% patients (ie; 17of them 
had IgG with combination of other autoantibodies), IgG alone was found in 32% 
patients (ie. Solitary IgG was found in 11 AIHA patients). Similarly in the study by 
Lai et al on AIHA patients he found that 55.6% of the patients had multiple 
autoantibodies and 44.4% had solitary IgG autoantibody.
142
 In contrast to this Das 
SS et al,. Found out that 68.5% of the AIHA patients in his study had single 
autoantibody.
 14
  
In this conjuncture, our study found that 80% of the AIHA patients with 
severe hemolysis had combination of antibodies in comparison to only 15% of 
AIHA patients with severe hemolysis who had solitary IgG antibody. This 
association was statistically significant with a p value <0.002. This findings in 
accordance to the studies conducted by Das SS et al and Wheeler et al 
respectively.
14,78 
  In our study C3d alone was identified in 6 (18%) of AIHA patients which 
raising the possibility of cold agglutination disease and 9% of the AIHA patients had 
mixed type AIHA having both IgG, C3d. Similarly in the study conducted by 
Shulman et al 8.3% of the patients having mixed type AIHA.
40
 
The present study experienced that out of 34 AIHA patients 30 (88%) had 
autoantibodies and 4 (12%) patients had both auto and alloantibodies.
 
Similarly, The 
study done by Wikman A et al had 28% of alloantibodies in AIHA patients all of 
them fell in moderate hemolysis group.
77
 Similarly the study conducted by Branch 
DR and Petz LD 25-47% of sera from AIHA patients showed the presence of 
alloantibodies.
141 
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IgG subtypes 
IgG1 was the most common subtype present in 11 (40%) patients, followed 
by IgG1 and IgG3 which was present in 8 (29%) patients and solitary IgG3 was 
found in 4 (14%) patients with AIHA. In our study 5 (17%) patients had neither 
IgG1 nor IgG3. In the study conducted by Das SS et al., 46.5% of AIHA patients, 
the subclass was IgG1 or IgG3 or both, while in the remaining patients, no IgG1 or 
IgG3 was detected.
14
 In the other study, IgG1 was the most frequent subclass (96%) 
coating the red cells.
29 
 The presence of both IgG1 and IgG3 has a significant effect on severity of 
hemolysis. A total of 8 patients were noted to have both IgG1 and IgG3 in which 7 
(87%) had severe hemolysis in par with 1 (13%) moderate hemolysis. A similar 
impact was noted in patients with solitary IgG1 [95% CI= 25.0570 to 88.9932; P = 
0.0042]. Among 11 AIHA patients with only IgG1 autoantibody 10 (90%) had 
severe hemolysis and 1 (10%) 95% [CI= 39.2760 to 91.4404; P = 0.0002] was 
having moderate hemolysis. Both of these associations were statistically significant. 
Among 4 AIHA patients who had IgG3 subclass, 3(75%) had moderate hemolysis 
and 1 (25%) had severe hemolysis. In 5 AIHA patients who had neither IgG1 nor 
IgG3, 4 (80%) had moderate hemolysis and 1 (10%) had severe hemolysis.  
Similarly in Das SS et al study 60% of the patients with combination of IgG1 
with IgG3 and IgG1 alone were more likely to present with severe hemolysis as 
compared to 21.7% of the patients having IgG3 only and neither IgG1 nor IgG3.
14
  
THERMAL AMPLITUDE 
 Out of 34 AIHA patients, 25(74%) warm autoantibodies reacted at 37˚C 
only, among 6 (18%) Cold AIHA in which 3 (9%) had thermal amplitude of 4˚C to 
22˚C and 3 (9%) had wide thermal amplitude of 4˚C to 37˚C. The remaining 3 
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patients belonged to Mixed type AIHA. In a similar type of study conducted by Das 
SS 81.4% was WAIHA, 16.3% were mixed type and there was only one cold AIHA 
(2.32%). 
14 
ELUTION (by Glycine Acid and Glycine Acid EDTA) 
Among the 34 DAT positive samples, Elution was done in all AIHA patients 
using commercially available kits, 28 elutes were reactive and 6 elutes were 
nonreactive. Among 28 reactive eluates 22 were showing panagglutination, in which 
21 (73%) were WAIHA with, 1 (4%) was due to mixed AIHA and 6 (23%) AIHA 
samples showed the presence of autoantibody specificity as anti-e which was 
confirmed with serum studies (4 were due to WAIHA and 2 were mixed 
AIHA).Similar to this a study conducted by Marilyn Johnston FM, Mary Kay 
Belota, observed that 68% of patients, in which 37% yielded positive eluates and 
63%, had nonreactive ones. Of the positive elution studies, 73% demonstrated only 
warm autoantibody on red blood cells. 2.5% of these had warm autoantibody in 
serum as well. 3% of these specimens were from previously but not recently 
transfused patients and had alloantibody/ies in serum. 33% eluates with positive 
results were from patients transfused 26-48 days before testing.
97
 Similarly Dacie JV 
in his study reported that Autoanti-e was the most common specificity; it has been 
pointed out that the reported relative incidence of different specific Rh 
autoantibodies corresponds well with the incidence of Rh antigens in the population 
(i.e., ‘e’ antigen is present on the RBCs of approximately 98% of the population).39 
Among 34 patients with AIHA Glycine Acid EDTA was carried out in 
patients who are diagnosed case of AIHA and in patients with h/o previous 
transfusion more than 3 months. Glycine Acid EDTA rendered DAT completely 
negative in 18 of the cases and in remaining 11 cases the strength of DAT is reduced 
than its original strength. Similarly in the study conducted by Katharia R Glycine 
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Acid EDTA 59 DAT positive samples showed decrease in reaction of which 22 
samples were DAT negative.
8 
5 WAIHA patients who were having IAT ≥ DAT further submitted to 
Autoadsorption to identify the presence of any Alloantibodies. Out of 5 patients all 
RBC coated autoantibodies were removed by Glycine Acid EDTA and the treated 
RBCs are used for Autoadsorption. The Autoadsorption revealed the presence of 
clinically significant alloantibodies in 4 out of 5 patients and one patient had no 
alloantibodies. Adsorptions with autologous RBCs, Laine and Beattie,
146
 James and 
colleagues,
147
 Issitt et al,
148
 and Morel and coworkers
149
 detected alloantibodies in 
27%, 32% , 38%, and 40% of sera, respectively. 
Autoantibody specificity 
In 19 of 34 (55%) autoantibodies reacting with all test erythrocytes 
(panagglutination) were detected, Autoantibodies with specificity against Rh antigen 
(anti-e) were identified in 5 of 20 patients in the group with severe haemolysis, in 1 
of 13 with moderate haemolysis and Autoantibodies with specificity against I 
antigen (anti-I) were identified in 1 of 20 patients in the group with severe 
haemolysis, in 5 of 13 with moderate haemolysis. Jenkins and coworkers found that 
sera containing cold autoagglutinins that had previously been called “nonspecific 
cold agglutinins” had anti-I specificity and it is more common to other cold 
autoantibodies.
100 
Auto and Alloantibody in AIHA vs Severity of hemolysis 
Alloantibodies were identified in 4/20 (20%) in relation to AIHA patients 
with severe hemolysis and all of them had previous history of transfusion. 3 of 4 
patients had single clinically significant alloantibody and 1 of 4 had multiple 
clinically significant alloantibodies. The association between transfusion and 
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alloantibody formation is statistically significant with a p value of 0.000. The study 
done by Wikman A et al had 28% of alloantibodies in AIHA patients all of them fell 
in moderate hemolysis group.
77
 Similarly the study conducted by Branch DR and 
Petz LD 25-47% of sera from AIHA patients showed the presence of 
alloantibodies.
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Hemolytic Diseases of Fetus and New-born (HDFN)   
DAT positivity in new-born is only due to HDFN either due to Rh 
incompatibility or due to ABO incompatibility between mother and fetus.  
Etiology 
 In our present study, Out of 21 cases of DAT positive HDFN cases received 
17 (81%) were due to Rh, 3 (14%) were due to ABO HDFN and 1(5%) is due to 
others. Similarly in the study conducted by Dharmesh Chandra Sharma et al Rh 
incompatibility was the commonest cause of HDN with 61 (55.5%) cases of RhD 
HDN whereas ABO and other group HDN cases were 30 (27.3%) and 19 (17.3%) 
respectively.
67 
Correlation of Hyperbilirubinemia (TSB >15mg/dl) with HDFN 
From a total of 21neonates, 16 (76%) with hyperbilirubinemia had TSB 
>15mg/dl, in which 5 infants needed ET and 16 were treated with phototherapy. The 
remaining 5 Infants who had mild hyperbilirubinemia TSB < 15mg/dl needed no 
intervention. Similarly in the study done by Swathi Chacham et al 41/48(85%) had 
hyperbilirubinemia with TSB >15mg/dl all of them needed Phototherapy and/or 
ET.
155 
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There is statistically significant correlation between hyperbilirubinemia 
with the management of HDFN and has a p value of < 0.000. (Mann-Whitney 
test / Two-tailed test) 
Mean HGB value in Moderate to Severe HDFN and mild HDFN patients 
Mean hemoglobin was assessed in patients with moderate to severe HDFN 
and mild HDFN by unpaired T test. The mean hemoglobin of moderate to severe 
hemolysis is 13.46gm/dl and of mild HDFN is 16.04gm/dl. Similarly Mollison et al,. 
stats that Moderately severe HDFN had a cord Hb concentration of 12.8 g/dl, and 
approximately 50% of the HDFN neonates had cord Hb concentrations of 14.5 g/dl 
or more, 30% had cord Hb values between 10.5 and 14.4 g/dl, and about 20% had 
Hb values of between 3.4 and 10.4 g/dl. The probability of survival diminishes as 
the cord Hb concentration falls. A level of 4 mg/dL or more of cord blood bilirubin 
(normal range, 0.7–3 mg/dL) or a rapidly rising bilirubin is suggested as an 
indication for exchange transfusion. If the cord total bilirubin is less than 4–5 mg/dL 
and rising only slowly, phototherapy might suffice to correct the problem.
109 
There is statistically significant difference in mean hemoglobin in 
patients with severe and moderate hemolysis (p ˂0.0013). 
Transplacental passage of maternal IgG results in antibody coating of the 
fetal red cells. High alloantibody concentrations lead to a strong DAT, whereas low 
concentrations or binding affinity result in a weak or, by traditional methods, often 
negative DAT. A strong positive DAT is observed particularly with anti-D; 
however, the reaction is more variable with alloantibodies against other Rh antigens 
and antigens such as Kell, Duffy, Kidd, and MNSs, which are well expressed on 
fetal red cells.
5 
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Correlation between Strength of DAT with severity of HDFN 
Out of 16 neonates with >2+ DAT strength 15 neonates had Moderate to 
severe HDFN and 1 neonates had  mild HDFN and among 5 neonates having <2+ as 
strength of DAT, 4 of them presented with mild HDFN and1 neonate was having 
Moderate to severe HDFN. A strong positive DAT is observed particularly with 
anti-D; however, the reaction is more variable with alloantibodies against other Rh 
antigens and antigens such as Kell, Duffy, Kidd, and MNSs, which are well 
expressed on fetal red cells.
5 
Correlation between Strength of DAT with severity of Rh HDFN 
 Out of 17 neonates with Rh HDFN 15 neonates with moderate to severe 
hemolysis had >2+ DAT strength and 2 neonates had <2+ as strength of DAT and 
presented with mild HDFN. There is significant correlation between Rh HDFN and 
severity of HDFN with a p value of 0.012.Similarly in a letter to editor written by 
Mustafa Aydin et al, they stated that severity of Rh HDFN is well correlated with 
strength of DAT.
151
  
Specificity of DAT in HDFN 
 Out of 21 cases of HDFN (100%) all of them had anti-IgG only in 
Monospecific DAT. Similarly in the study conducted by Pollock & Bowman only 
IgG was the only antibody identified in cases of HDFN.
30
  
IgG subtype of DAT in HDFN 
Out of 21 HDFN cases, IgG1 was identified in (11) 52% of the neonates; 
IgG1 & IgG3 (6) were found in 29% of the neonates, IgG3 was found in (3)14% of 
the neonates and neither IgG1 nor IgG3 were seen in 5% (1) neonate. Similarly in a 
study done by Frankowska and Gorska, they found that 87.6% had IgG1 Rh 
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antibodies, 23% contained IgG2 antibodies, 56.9% contained IgG3 antibodies, and 
7.7% contained IgG4 antibodies.
31
 
 
Correlation between IgG subclass and severity of HDFN 
Out of 17 Rh HDFN 2 neonates had mild HDFN and 15 neonates had 
Moderate to severe HDFN. The distribution of IgG1, IgG1& IgG3 and IgG3 was 11 
(65%), 3 (14%) and 3 (14%) respectively among the neonates with Rh HDFN. This 
present study has statistical significance between the subclass and severity of Rh 
HDFN. Similarly, Nance et al., in their study found that severe HDN was associated 
with IgGl antibodies more frequently than with IgG3 antibodies.
144
  
Glycine Acid Elution 
 Among the 21 neonates acid elution was done in all the infants. 20(95%) 
eluates were reactive and 1(5%) eluate of ABO HDFN was nonreactive.  
In this study there is a statistically significant correlation between the DAT 
positive neonates and antibody identification in the eluate with a p value of <0.0001. 
R.H. Finck et al., in their study found that antibodies eluted from cord blood RBCs 
was 100% (7 of 7). He also mentioned that apart from ABO HDFN all other 
antibody mediated HDFN can be diagnosed antenatally. However, Elution can be of 
useful value in diagnosing clinically significant ABO HDFN and difficulty in 
obtaining maternal serum for other HDFN.
96 
Glycine Acid EDTA Elution in HDFN 
Out of 21 HDFN samples Glycine Acid EDTA elution was done in all the 
samples and DAT was rendered negative. Rh phenotyping along with other specific 
phenotypes were identified in the above treated RBCs. However kell antigens (K,k) 
were destroyed by this elution method. Rahul Katharia et al in his study found that 
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the best method for obtaining antibody free DAT positive RBCs is Glycine Acid 
EDTA.
8 
Antibodies found in neonates with HDFN by elution 
 Out of 17 Rh HDFN neonates Anti-D was found in 13 (76%) neonates, anti-
D & anti-C was found in 2 (12%) neonates, anti-c was found in 2 (12%) neonates 
only. Among 3 ABO HDFN Anti-A was found in 1 Neonate and Anti-B was found 
in 1 neonate and among other blood group antigens anti-M was found in 1 neonate. 
Huub H.vanRossum et al., study explains the high sensitivity of both techniques 
(DAT and Elution) on detecting neonatal erythrocytes sensitized with anti-A and 
anti-B as the maternal serum can be used to detect the HDFN due to other blood 
group antigens.
77
 R.H. Finck et al., stated in his study that elution can be of useful 
value in diagnosing clinically significant ABO HDFN and difficulty in obtaining 
maternal serum for other HDFN.
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DELAYED HEMOLYTIC TRANSFUSION REACTIONS (DHTRs): 
 A transfusion reaction can be classified as an DHTR only if evidence of 
hemolysis (i.e., reduced red cell survival) is documented.  
III. a. The strength of polyspecific DAT in DHTR 
 Out of 2 cases 1 had 3+ in polyspecific DAT and 1 had 1+ reaction in 
polyspecific DAT. 
III. b. Features of Hemolysis 
 HGB gm/dl TSB mg/dl LDH IU/ml Retic 
Patient 1 7.3 2.8 615 4% 
Patient 2 8.8 2.4 532 2% 
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Pineda et al. in his study found out that the most constant features of DHTRs 
are fever and a fall in Hb concentration. Other features that are often observed are 
jaundice and rarely haemoglobinuria.
104 
Erwin Strobel In his study describes that in case of a DHTR, rise in bilirubin, 
reduction of haptoglobin, and sometimes slightly elevated free hemoglobin in the 
patient’s plasma can be found. In some cases, hemoglobinuria may also occur. The 
hemoglobin value of the patient will drop again about 1–2 weeks after blood 
transfusion without bleeding or other known reasons. The reticulocyte count will 
rise if the patient’s disease allows this reaction, and in the blood smear spherocytes 
can be seen.
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III. c. Distribution of antibodies by monospecific DAT 
  Out of 2 cases of delayed hemolytic transfusion reactions both of them had 
IgG and C3d in their coated RBCs identified by monospecific DAT. Salama and 
Muller-Eckhardt 
35 
in their study found that all the patients were found to have both 
IgG and C3d antibodies detected on their RBCs after the delayed hemolytic reaction. 
RBC bound C3d is detectable by DAT for weeks and even months after the 
transfusion. Similarly O Nathalang el at., in their study found that most of the 
patients who had IgG antibodies or IgG and C3d coated on their RBC (91.6%) had a 
history of blood transfusions.
154
  
III. d. Distribution of IgG subtypes 
Both patients of delayed hemolytic transfusion reactions had IgG1 subclass 
with 1:1 dilution which was identified by IgG subclass card. IgM, IgG3, and IgG1 
are able to start the classical pathway of complement activation, IgG3 and IgG1 also 
can initiate extravascular RBC clearance without complement activation.
36, 82 
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IV. e. Elution in DHTR 
 In Glycine Acid elution of both DAT positive DHTR samples we found the 
presence of Anti-Jk
a
 and anti-c both are clinically significant antibodies. However 1 
antibody (Anti-c) was found in serum of the patient. Vamvakas et al in their study 
found that the prevalence of DHTR was higher when the implicated RBC 
alloantibody was anti-Jk
a
 with a p value of <0.000.
157
 In the study conducted by 
Ness et al Alloantibody was eluted from the RBCs of all patients.
36 
Hoeltge and 
coworkers studied alloimmunization and found the most common specificities were 
anti- K (23%), anti-E (18%), anti-D (12%), anti-Lea (7.3%), anti-C (6.3%), anti-Fya 
(5.7%), anti-c (4.4%), and anti-Jka (3%).
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Glycine Acid EDTA Elution  
Glycine Acid EDTA Elution was not performed in both the DHTR patients 
since they had h/o transfusion 6 days and 10 days back respectively.  
Elution of DAT positive samples in overall view   
A total of 57 eluates were analysed during the study period. There was a total 
of 20(35%) non anti-A/B alloantibodies (mainly among HDFN and DHTR cases) 
were recovered from 57 eluates. Among the 24 (42%) warm autoantibodies [6 
(11%) were having Autoanti-e specificity and remaining 18 (32%) were 
panagglutinating autoantibodies]. Anti-A/B alloantibodies were eluted from 2 (4%) 
out of 3 ABO HDFN neonates. 4 (7%) of WAIHA patients had both auto and 
alloantibodies. Similarly in the study done by Mark Yazer there was 12.4% nonanti-
A/B alloantibodies were recovered; 43.8% warm autoantibodies and 1.5% had both 
auto and alloantibodies.
153
 In our study 16 were informative eluates in which serum 
antibody detection was negative. However, among these only 3 eluates had antibody 
specificity (2 anti A/B and anti Jka) remaining 13 were panagglutinins. In a study 
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done by R.H. Finck he found that in HDFN out of 7 cases informative eluates were 
found in 5 cases all of them belonged to ABO HDFN remaining 2 belonged to Rh 
HDFN and they also present in maternal serum.
 96
  
Overall rate of informative eluates in our study was 5.3% excluding the 
panagglutinins and 1.9% of these informative eluates were due to DHTR. Similarly, 
in the study done by Mark Yazer Overall rate of informative eluates was 12.7%. 
Further, 1.7% of these informative eluates were due to DHTR.
 153
 Similarly Johnston 
and Belota found only two (2.4%) eluates that revealed a new alloantibody in the 
eluate which was not in the serum. Both of these patients suffered a delayed 
hemolytic reaction.
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Glycine Acid EDTA Elution 
 Among 57 patients with DAT positivity Glycine Acid EDTA was carried out 
in 50 DAT positive patients who are diagnosed to have AIHA and HDFN. This 
implies that Glycine acid EDTA was not done 3 cases of CAS, 2 AIHA patients with 
a recent history of transfusion (< 7days) and also in 2 cases of DHTR. Glycine Acid 
EDTA rendered 39 samples (18 AIHA and 21 HDFN) of DAT completely negative 
and in the remaining 11 (AIHA) cases the strength of DAT is very much reduced 
than its original strength. In the study done by Rahul Katharia et al., they found that 
among 93 DAT positive samples, 59 samples showed decreased strength and 22 
were DAT negative.
8
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SUMMARY 
The present study on evaluation of DAT positive cases by elution study is 
done by assessing serological characterization of red cell bound antibodies with 
regard to antibody class, subclass, DAT strength and their correlation with in vivo 
haemolysis. The specificity of the auto and alloantibodies was identified by using 
eluate prepared from acid elution technique. The presence of additional alloantibody 
is identified after auto-adsorption with Glycine Acid EDTA treated cells. Further, to 
confirm the specificity of the antibodies, the red cells (treated with Glycine Acid 
EDTA) were phenotyped for the corresponding antigens, 
 Our study included total number of 57 DAT positive cases. 
 Among 57 DAT positive cases 34 were AIHA, 21 were HDFN and 2 were 
DHTR. 
 In 34 AIHA patients, 25 were WAIHA, 3 belonged to Mixed AIHA and 6 
were due to Cold AIHA. 
 In general, the gender distribution among AIHA patients was (male: 
female ratio) 1:2. 
 20 (56%) patients were diagnosed as Primary AIHA and 14 (44%) 
patients as Secondary AIHA. 
 The most common cause for secondary AIHA was due to Systemic 
Autoimmune disorders [SLE (n=4) & Rheumatoid Arthritis (n=1)].  
 Other cases were associated with Sickle Cell Anaemia (n=2), 
Lymphoproliferative Disorders (n=3), Pure Red Cell Aplasia (n=1), 
Ovarian Tumours (n=2), HIV (n=1), and Carcinoma Cervix (n=1). 
 Out of 24 cases with more than 2+ DAT strength, 18 showed severe 
hemolysis. 
 17 cases (50%) showed IgG class of Immunoglobulins along with IgM, 
IgA and /or Complements. 
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 11 cases (32%) showed exclusively IgG class of Immunoglobulins. 
 6 cases (18%) showed only the presence of Complements. 
 Out of 20 cases of severe hemolysis, 16 had combinations of various 
classes of Immunoglobulins along with Complements (IgG & C3d 11, 
IgG & IgA 2, IgG, IgM & C3d 1and IgG, IgM, IgA &C3d 2). 
  Out of 28 cases with the presence of IgG Immunoglobulins (IgG alone 
11,IgG & C3d 12, IgG & IgA 2, IgG, IgM & C3d 1and IgG, IgM, IgA 
&C3d 2). 
 Out of 28 cases with IgG Immunoglobulins, 11 had IgG 1 subclass, 8 had 
IgG1 & IgG3, 4 cases had IgG3. 5 cases belonged to neither IgG1 nor 
IgG3. 
 Out of 6 cases with the presence of only complements, 3 showed reaction 
at 4 
o 
C to 37 
o
 C in which 1 (17%) showed severe hemolysis with titre of 
2048. 
 Out of 34 cases, 30 (88%) AIHA patients had autoantibodies and 4 
(12%) patients had both auto and alloantibodies, these 4 cases had 
previous history of transfusion. The alloantibodies identified were Anti-C 
(1), Anti-E (1), anti-c (1) and anti Fya along with anti-S in (1) patient. 
 Out of 30 cases with only autoantibodies, 6 cases WAIHA (n=-4) and 
Mixed AIHA (n=2) showed anti-e specificity, 6 cases of cold AIHA 
showed anti-I specificity, the remaining 18 cases showed 
panagglutination. 
 In 21 DAT positive cases of HDFN 17 (81%) were due to Rh HDFN, 3 
(14%) were due to ABO HDFN and 1(5%) case was due to anti-M 
antibodies. 
 Out of 17 neonates with Rh HDFN 15 neonates with moderate to severe 
hemolysis had >2+ DAT strength and 2 neonates had <2+ as strength of 
DAT and presented with mild HDFN. 
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 All the 21 DAT positive HDFN neonates had only IgG antibody in their 
RBCs, including 3 cases of ABO HDFN. 
 Out 21 HDFN neonates, IgG1 was identified in (11) 52% of the 
neonates; IgG1 & IgG3 (6) were found in 29% of the neonates, IgG3 was 
found in (3)14% of the neonates and neither IgG1 nor IgG3 were seen in 
5% (1) neonate.  
 All 15 neonates with moderate to severe hemolysis had IgG1 subclass or 
IgG1 along with IgG3 subclass of Immunoglobulins. 
 The neonate with neither IgG1 nor IgG3 showed anti-M antibody. 
 Out of 21 eluates 20 were informative with presence of alloantibodies. 
The nonreactive eluate prepared from the remaining one neonate 
belonged to ABO HDFN, which showed anti-A specificity on cold 
elution. 
 Out of 20 eluates 16 were compared and confirmed with maternal serum.  
 Among 2 cases of DHTR, 1 had “anti-Jka” and the other had “anti-c” 
antibody. 
 Monospecific DAT on coated RBCs from these 2 cases revealed 
presence of both IgG class of Immunoglobulins and C3d. 
 Both patients of delayed hemolytic transfusion reactions had IgG1 
subclass. 
 Both the patients had history of previous transfusion and showed features 
of hemolysis. 
 Out of these 2, anti-Jka was identified in the eluate only and anti-c was 
identified in both serum and eluate. 
 The RBCs treated with Glycine Acid EDTA from the total of 57 cases, 27 
cases (6 cases of AIHA and 21 cases of HDFN) showed the presence of 
corresponding antigen. 
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CONCLUSION 
 
 In our study on evaluation of DAT positive cases by elution study revealed a 
strong association between DAT strength and the severity of hemolysis. Further, we 
observed that the presence of IgG immunoglobulins in combination with IgM, IgA 
and complements elicit severe hemolysis in AIHA cases in comparison to exclusive 
presence of only IgG. However, in cases of HDFN the pathogenesis of hemolysis 
was exclusively due to the presence of IgG.  
Our study included two cases of DHTR, one was due to anti-c and another 
was due to anti-Jka, in both these cases we found these antibodies along with 
complements. In all cases of DAT positive hemolysis with the presence of IgG 
immunoglobulins irrespective any aetiology, the most common subclass identified 
was IgG 1 and IgG 3. 
In six of cold AIHA cases in our study, one case had shown severe 
hemolysis due to the presence of high-titre (2048) anti-I antibody along with 
complements.  
The specificity of auto and alloantibodies were identified by adsorption and 
elution techniques, which revealed exclusively anti-e in 6 cases of WAIHA and 4 
cases with previous history of transfusion had panagglutinating autoantibodies along 
with the presence of clinically significant alloantibodies. 
Our study suggests a significant association between the strength of DAT, 
the IgG class and subclass (IgG 1 & IgG 3) of Immunoglobulins either alone or in 
combination with other classes of immunoglobulins and/or complements.  
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The Glycine Acid EDTA elution in DAT positive immune haemolytic 
anemia cases provide uncoated RBCs for exact phenotyping and autoadsorbed 
serum for cross match compatibility. This study further reiterates the importance of 
acid elution in DAT positive of HDFN and DHTR cases in identification of the 
specific alloantibody. 
 Further, this study reinstates a schematic approach in dealing with DAT 
positive immune haemolytic anemia cases by designing institutional based algorithm 
for efficient patient management. 
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LIMITATIONS OF THE STUDY 
1. This study does not represent the true prevalence of AIHA, HDFN and 
DHTR since MMC and Department of Transfusion Medicine, The TN 
Dr.M.G.R Medical University are   referral centres.  
2. Criteria for assessing severity of haemolysis was derived from a previous 
publication from Wheeler et al, Das SS et al and Mishra JP et al as no 
clinical guidelines available for the   same.  
3. Patients recruited for the study belonged to different time points in the course 
of their disease. 
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PARTICIPANT CONSENT FORM 
 
Participant’s name:                                                           Address: 
 
 
EVALUATION OF DIRECT ANTIGLOBULIN TEST POSITIVE CASES 
BY ELUTION STUDIES 
 
            The details of the study have been provided to me in writing and explained to 
me in my own language. I confirm that I have understood the above study and had 
the opportunity to ask questions. I also understand that my participation in the study 
is voluntary and that I am free to withdraw at any time, without giving any reason, 
without the medical care that will normally be provided by the hospital being 
affected. I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). I have been given an 
information sheet giving details of the study. I fully give my consent to participate in 
the above study. 
 
 
Signature of the Participant:                                                             Date:          
     
 Signature of the Witness:                                                                Date:          
 
Signature of the Investigator:                                                           Date:          
CONSENT FORM (for participants less than 18 years of age) 
 
Participant’s name:                                                           Address: 
Parent/LAR’s name:               
 
EVALUATION OF DIRECT ANTIGLOBULIN TEST POSITIVE CASES 
BY ELUTION STUDIES 
            The details of the study have been provided to me in writing and explained to 
me in my own language. I confirm that I have understood the above study and had 
the opportunity to ask questions. I also understand that my child/ward’s participation 
in the study is voluntary and that I am free to withdraw my child/ward at any time, 
without giving any reason, without the medical care that will normally be provided 
by the hospital being affected. I agree not to restrict the use of any data or results 
that arise from this study provided such a use is only for scientific purpose(s). I have 
been given an information sheet giving details of the study. I fully give consent for 
the participation of my child/ward in the above study. 
 
Assent of  child/ward(for participant’s 7 to 18 years of age) 
 
Signature of the Parent/LAR:                                                           Date:          
     
 Signature of the Witness:                                                                Date:          
 
Signature of the Investigator:                                                           Date:          
PATIENT INFORMATION SHEET 
  
TITLE OF THE STUDY 
                            Elution studies in DAT positive cases 
NAME OF THE INVESTIGATOR 
Dr.G.Kavitha, 2
ND
 Year P.G, MD (IH & BT) 
The TN Dr.M.G.R Medical University, 
Guindy, Chennai-32 
NAME OF THE GUIDE: 
Dr.Swathandran Hamsavardhini, MD(IH&BT), 
Associate Professor, 
Department of Transfusion Medicine, 
The Tamilnadu Dr.M.G.R. Medical University, 
Chennai-32.               
PURPOSE OF THE STUDY                   
The direct antiglobulin test is used most commonly to investigate possible 
haemolytic transfusion reactions, haemolytic disease of the fetus and newborn 
(HDFN), autoimmune haemolytic anaemia and drug induced immune haemolysis. 
Elution removes antibody molecules from the red cell membrane either by 
disrupting the antigen or changing conditions to favor dissociation of antibody from 
antigen. Many techniques are available, and no single method is best in all 
situations. If an eluate prepared by one technique is unsatisfactory, it may be helpful 
to prepare another eluate utilizing a different technique. 
PROCEDURE: 
               After getting consent from the patient, complete details regarding the 
patient which includes name, age, gender, IP number, clinical diagnosis of the 
patient will be obtained from the questionnaire by the principal investigator. 5ml of 
patient’s blood is collected in EDTA tube. Blood grouping and typing, DAT, IAT 
and AutoControl, Antibody screening and Identification and Elution will be 
performed at the The Department of Transfusion Medicine The Tamilnadu 
Dr.M.G.R. Medical University, Guindy, Chennai. Acid alters charge of proteins 
causing a change in structural configuration. Most allo and autoantibodies are 
detected by acid elution technique.  
DURATION 
August 2017 to September 2018.                 
BENEFITS AND RISKS 
                We can differentiate between auto and allo antibody. Based on which 
treatment can be changed and antigen matched blood can be transfused which will 
save the life of the patient. 
               There will be less than minimal risk for patients enrolled as it is a 
continuous process of routine investigation. 
 CONFIDENTIALITY 
               Your privacy will be protected as permitted by law. Only your researcher 
and ethical committee members will have access to data collected during the study. 
PARTICIPATION 
           Your participation in this study is voluntary and you are free to decide now 
are later whether to continue or discontinue from the study any time without giving 
any reason, the medical care to you will be normally provided by the hospital. Your 
data or results that are generated from this study will be used or shared only for 
scientific purpose(s). 
I. Investigator: 
Dr.G.Kavitha , 
MD(IH&BT),Post Graduate student, 
The TN Dr.M.G.R medical University, 
Guindy, Chennai. 
 
 
 
II. Guide: 
Dr.Swathandran Hamsavardhini, MD(IH&BT), 
Associate Professor, 
Department of Transfusion Medicine, 
The Tamilnadu Dr.M.G.R. Medical University, 
Chennai-32. 
 
III. Co-Guide: 
DR.Margret,MD.,DM., 
Professor and Head, 
Department of Hematology, 
Rajiv Gandhi General Hospital, 
Chennai. 
 
 
NAME OF THE PATIENT  : 
SIGNATURE                       : 
DATE                                   : 
 
 
Signature of the Investigator:                                                           Date:                                     
 
  
PROFORMA FOR DAT POSITIVE CASES 
 
Patient’s Name:                                                                         Hospital Number: 
Address: 
Patient’s ABO/D typing:                                                            Patient’s DAT    : 
H/o Previous transfusion : 
H/o pregnancy: 
H/o associated illness: 
H/o Transplantation: 
Drug history : 
Hematology & Biochemical Markers of Hemolysis: 
           Hb (gm/dl)  : 
           Reticulocyte count  : 
           S.bilirubin (mg/dl)  : 
           LDH (IU/ml)  : 
 Serological Evaluation: 
           DAT Strength  : 
           Polyspecific card : 
           Monospecific card : 
           IgG Subclass     : 
Elution Procedure: 
(Acid elution)   : 
  
Antibody Screening and Identification; 
 Reactions with eluate  Reactions with Last Wash Control 
3 cell panel   
11 cell panel   
 
REACTIVE   : 
NON-REACTIVE  : 
 
Glycine Acid EDTA Elution : 
DAT Strength   : 
NEGATIVE   : 
Decreased   : 
 
Interpretation of elution results: 
 
Date: 
 
 
                     
  
ந ோயோளியின் ஒப்புதல் படிவம் 
 
ஆராய்சச்ியாளர ் என்னிடம் இந்த ஆய்வானது இரத்த 
சிவப்பு அணுக்களுக்கு எதிராக உண்டாகும் 
ஆண்டிபாடிகளினால் ஏற்படும் இரத்தசசாககக்கானது என்று 
எடுத்துக் கூறினார.் இதற்காக சுமார ் 5மி.லி இரத்தம் 
என்னிடமிருந்து எடுத்து பரிசசாதகன சசய்யப்படும் என்று 
விளக்கினார.் நான் இந்த ஆய்வில் பங்குசபற முழுமனதுடன் 
சம்மதிக்கிசறன். சமலும் கூடுதல் பரிசசாதகன இந்த 
ஆய்வுக்காக சதகவப்படுசமயானால் அதற்கும் முழுமனதுடன் 
சம்மதிக்கிசறன். இதனால் எனது சிகிசக்ச எந்த விதத்திலும் 
பாதிக்காது என்பதகனயும், இந்த ஆய்விலிருந்து எந்த 
சநரத்திலும் விலக எனக்கு உரிகம உள்ளது எனவும் 
ஆராய்சச்ியாளர ்விளக்கினார.் 
 
சநாயாளியின் சபயர:் 
ககசயாப்பம்: 
சததி: 
 
  
பங்நேற்போளரே்ளுே்ேோன தேவல் படிவம் 
 
இரத்தமழிவுச ்சசாககயில் இரத்த சிவப்பு அணுக்களுக்கு 
எதிராக ஏற்படும் ஆண்டிபாடிகளின் தன்கம குறித்து 
கண்டறியும் ஆய்வு. 
குறிே்நேோள்: 
சாத்தியமான தன்னுடல் சதாற்றமுள்ள ஆண்டிபாடிகளி 
னால் ஏற்படும் இரத்தமழிவு  சசாகக, மருந்து தூண்டப்பட்ட 
சநாய் எதிரப்்பு ஆண்டிபாடிகளினால் ஏற்படும் இரத்தமழிவுச ்
சசாகக கரு மற்றும் பிறப்பு (செசஷ்எஃப்என்) இரத்தமழிவுச ்
சசாககயில், இரத்த சிவப்பு அணுக்களுக்கு எதிராக ஏற்படும் 
ஆண்டிபாடிகளின் தன்கம குறித்து கண்டறிய ஆய்வு 
சமற்சகாள்ளப் படும். ஆய்வு சசய்ய சநரடியாக எல்யூஷன் 
சசாதகன பயன்படுத்தப்படுகிறது. சிவப்பு சசல் சவ்வு இருந்து 
ஆன்டிபாடி மூலக்கூறுககள நீக்குதல் அல்லது ஆன்டிசெனின் 
இருந்து ஆன்டிபாடி விலகல் ஆதரவாக மாற்ற நிகலகள் 
மாற்றுவதன் மூலம். பல நுட்பங்கள் கிகடக்கின்றன, எல்லா 
சூழ்நிகலகளிலும் எந்த ஒரு எல்யூஷன் முகறயும் சிறந்ததல்ல. 
ஒரு சதாழில் நுட்பத்தால் தயாரிக்கப்படும் ஒரு தூண்டுதல் 
திருப்தியற்றதாக இருந்தால், சவறு நுட்பத்கத 
உபசயாகிப்பதற்கான மற்சறாரு உதவிகய தயாரிக்க 
உதவியாக இருக்கும். 
செய்முறற: 
சநாயாளியின் அனுமதியின்சபாது, சநாயாளியின் சபயர,் 
வயது, பாலினம், ஐபி எண், சநாயாளிக்கு மருத்துவ சநாயறிதல் 
ஆகியகவ அடங்கும் சநாயாளிக்கு முழுகமயான விவரங்கள் 
முதன்கம புலன்விசாரகணயாளரால் சகள்வி சகடக்ப்படும். 
சநாயாளியின் இரத்தம் 5ml EDTA குழாயில் சசகரிக்கப்படுகிறது. 
இரத்த பிரிவு மற்றும் தட்டசச்ு, DAT, IAT மற்றும் AutoControl, 
ஆன்டிபாடி ஸ்கிரீனிங் மற்றும் அகடயாளம் காணல் மற்றும் 
எல்யூஷன் இரத்த பரிசசாதகன டாக்டர ் எம்.ஜி.ஆர ் மருத்துவ 
பல்ககலகழகத்திலலுள்ள குருதிசயற்று துகறயில் ஆய்வுக்கு 
உட்படுத்தப்படும். 
படிப்பு ேோலம்: 
ஆக] ;ட் 2017 முதல்  சசப்டம்பர ்2018 வகர 
பலன்ேள்: 
இரத்தமழிவுச ்சசாககயில் இரத்த சிவப்பு அணுக்களுக்கு 
எதிராக ஏற்படும் ஆண்டிபாடிகளின் தன்கம குறித்து கண்டறிய 
இந்த ஆய்வு உதவும். சமலும் சநாயாளிகளின் இரத்தவகககய 
கண்டறிந்து அவரக்ளுக்கு சரியான சிகிசக்ச அளிக்க உதவும். 
போதிப்புேள்: 
இது வழக்கமான பரிசசாதகனகளின் சதாடரச்ச்ியான 
சசயல்முகற என்பதால் பதிவுசசய்யப்பட்ட சநாயாளிகளுக்கு 
இடர ்குகறவாக இருக்கும். 
இரேசியபோதுேோப்பு: 
உங்கள் மருத்துவ தகவல் (தனிப்படட் விவரங்கள், உடல் 
பரிசசாதகன, விசாரகண, மற்றும் உங்கள் மருத்துவ வரலாறு) 
பற்றிய தனியுரிகம சதாடரப்ாக இரகசியத்திற்கு உரிகம 
உள்ளது. இந்த ஆவணத்தில் ககசயழுத்திடுவதன் மூலம், 
உங்கள் தரகவ பாரக்வயிட, ஆராய்சச்ிக் குழு விசாரகண, 
மற்ற ஆய்வுப் பணியாளரக்ள் மற்றும் நிறுவன சநறிமுகறகள் 
குழு ஆகியவற்கற அனுமதிக்க சவண்டும். விஞ்ஞான 
சஞ்சிகககளில் சவளியிடப்பட அல்லது விஞ்ஞானக் 
கூட்டங்களில் பங்சகற்க  அனுமதி வழங்கப்பட்டிருந்தால், இந்த 
ஆய்வின் தகவல்கள் உங்கள் அகடயாளத்கத எந்தவிதத்திலும் 
சவளிப்படுத்தாது. 
பங்ேளிப்பு: 
இந்த ஆராய்சச்ியில் தங்களின் பங்சகற்பு முற்றிலும் 
தன்னாரவ்மாக உள்ளது. எந்தசவாரு காரணமும் இன்றி இந்த 
ஆய்வில் எந்த சநரத்திலும் ஆய்வுக்குப்பின் எந்த சநரத்திலும் 
திரும்பப் சபற உங்களுக்குஉரிகம உள்ளது. இருப்பினும், 
நீங்கள் சிகிசக்சகய நிறுத்துவதற்கு முன்னர ் ஆராய்சச்ி 
குழுவிடம் சபசுதல் / சசயல்முகறககள நிறுத்துதல் 
சபான்றவற்கறப் பரிந்துகரப்பது நல்லது. இந்த ஆராய்சச்ியில் 
பங்சகற்க சவண்டாம் என்ற உங்களின் 
முடிவினால்,தங்களுக்குமருதத்ுவ ரக்ளின் பராமரிப்பு அல்லது  
உங்களின் மருத்துவ சிகிசக்சஅல்லது மருத்துவமகனயுடன்  
உங்கள் உறவு பாதிக்காது. நீங்கள் கவனித்துக் 
சகாள்ளப்படுவீரக்ள், உங்களுக்குரிய எந்த நன்கமகயயும் 
நீங்கள் இழக்க மாட்டீரக்ள். இந்த ஆய்விற்கான சிகிசக்ச 
மற்றும் ஆராய்சச்ியின் சசலவிற்கான பணம் உங்களிடமிருந்து 
சசகரிக்கப்படாது. 
 
ந ோயோளியின் சபயர்: 
றேசயோப்பம்: 
இடம்: 
நததி: 
I. ஆய்வோளர ்
மரு.சகா.கவிதா 
மருத்துவ முதுககல பட்டப்படிப்பு மாணவி, 
தமிழ்நாடு டாக்டர ்எம்.ஜி.ஆர ்மருத்துவ பல்ககலக்கழகம் 
கிண்டி,சசன்கன. 
II. வழிேோட்டி                                                               
மரு. சுதந்தரன் ெம்சவரத்ினி, எம்.டி, 
இகண சபராசிரியர,் 
குருதிசயற்று துகற 
தமிழ்நாடு டாக்டர ்எம்.ஜி.ஆர ்மருத்துவ பல்ககலக்கழகம் 
கிண்டி,சசன்கன. 
III. இறை வழிேோட்டி: 
மரு. மாரக்சரட,்  எம்டி., டி.எம்., 
சபராசிரியர ்மற்றும் தகலவர,் 
குருதியியல் துகற , 
ராஜீவ் காந்தி சபாது மருத்துவமகன, 
சசன்கன. 
  
GRADING OF AGGLUTINATION 
 
Figure 2 
0/NEGATIVE: Well-defined pellet of non-agglutinated red blood cells at the 
bottom of the gel column and no visible agglutinated cells in the rest of the gel 
column. 
w+:Barely visible small-sized clumps of agglutinated cells in the lower part of the 
gel column and a pellet of unagglutinated cells at the bottom. 
1+: Some small-sized clumps of agglutinated cells most frequently in the lower half 
of the gel column. A small pellet may also be observed at the bottom of the gel 
column. 
2+: Small or medium-sized clumps of agglutinated cells throughout the gel column. 
A few unagglutinated cells may be visible at the bottom of the gel column. 
3+: Medium-sized clumps of agglutinated cells in the upper half of the gel column. 
 4+: A well-defined band of agglutinated red blood cells in the top part gel column. 
A few agglutinated cells may be visible below the band.  
Mf:  Mixed-field. A band of red blood cells at the top part of the gel or dispersed 
throughout the gel column, and a pellet in the bottom as a negative result. 
H: Hemolysis in the microtube with very few or no red blood cells in the gel 
column. Report if hemolysis is present in the microtube but not in the sample. 
  
MONOSPECIFIC DAT 
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IgG SUBCLASS 
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ELUATE TESTING II 
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GLYCINE ACID ELUTION KIT 
 
Figure 5 
 
                                                      GLYCINE ACID EDTA KIT 
 
Figure 6 
 
RBC Elution  
 
 
Figure 1 
 
Picture Courtesy: Hendrickson & Tormey 
Comparison Chart of DAT positive AIHA cases 
Parameters  Present study Petz LD 
Dacie 
JV 
Wheeler 
et al 
Sokol et al
 
SS Das et al Wikman Lai et al 
Distribution of 
AIHA 
Primary 59%    57% 44%   
Secondary 41% 43% 56% 
Age Primary >40 yrs 58% >40 yrs 
73% 
      
Secondary <40 yrs 57% 
Type of AIHA wAIHA 74% 70.3%   62.8%    
Cold AIHA 17% 15.6% 29.3 
Mixed  9%  6.9% 
M:F ratio Primary 1:2.2  F:58% 1.27:1 1.15 to 1:1.33 1:3.3   
Secondary 1:1.8 
Severity of AIHA Primary 60%     52.9% yes  
Secondary 40%  47.1% 
DAT vs severe 
hemolysis 
>2+ 75%   86%  70% 42%  
<2+ 10% 14% 15% 0% 
Distribution of 
autoAbs 
IgG & other Abs 50%  51%  36.9%  
 
59% 55.8% 
IgG alone 32% 36%  34% 44.2% 
C3d alone 18% 11%  9%  
Multiple autoAbs vs  
severe Hemolysis 
Multiple Abs 80%    yes 83.3%   
Solitary IgG 15%    22.6% 
Auto & Allo Abs  12% yes       
Distribution of  IgG 
sub type of autoAbs 
IgG1 40%  42%  63.1% 37.2%  59% 
IgG1&IgG3 49% 14% 34.9% 9.3% 33.3% 
IgG3 11% -   7.7% 
IgG Sub type of vs  
severe Hemolysis 
IgG1 7/8 (87%)     59%   
IgG1&IgG3 10/11 (90%)  
IgG3 1/3 (25%)  
Comparison Chart of DAT positive AIHA cases 
Parameters  
Present 
study 
Petz LD 
Johnston 
FM study 
Dacie JV 
Katharia 
R et al 
Yazer 
MH et al 
Wikman 
A et al 
Laine 
and 
Beattie, 
SS das 
et al 
Elution Acid Elution yes     yes    
Gly Acid 
EDTA 
yes yes   
Reactivity of 
Eluate 
Reactive 71% Yes 37% yes  62.3%    
nonreactive 29%  63%  37.7%  
DAT 
Strength 
Negative 19 (62%)    37%     
decreased 9 (38%) 63%    
AutoAb 
specificity 
Anti-e 21% Anti-e 
(M/c) 
 yes      
Anti-I 6/6 
(100%) 
91%  
Auto & allo 
Ab 
      12% Yes     28% 37.6% 37.6% 
Thermal 
Amplitude 
> 37˚C 25 (74%)        81.3% 
4˚C to 37˚C  6 (17%)  16.3% 
4˚C to 22˚C  3 (9%)   
 
 
  
Comparison Chart of DAT positive HDFN cases 
 
Parameters  Present Study 
Dharmesh 
et al 
Frankowska 
et al 
Pollock 
Nance et 
al 
Greco et al 
Mustafa 
Aydin et al 
Etiology Rh HDFN 80% 55.5%      
ABO 14% 27.3% 
others 6% 17.3% 
Strength of 
DAT vs 
hemolysis  
<2+ 16 (76%)      yes 
>2+ 5 (24%) 
Specificity IgG only 21/21   98/98    
IgG subtype in 
HDFN 
IgG1 52%  34% 32.6%    
IgG1&3 29% 32% 64.2% 
IgG3 14% 10% 3.1% 
No IgG1&/3 5% 7.7%  
IgG subclass vs 
severity of 
HDFN 
IgG1 81% Tt    56% Tt   
IgG1&3 100% Tt 90% Tt 
IgG3 33% Tt 47% Tt 
Elution IgG1&3 20     34  
IgG3 1 1 
 
Comparison Chart of DAT positive DHTR cases 
 
Parameters  Present study Pineda et al Erwin Strobel Salama Ness et al 
Johnston et 
al 
Strength of DAT 1+ 1      
2+ 1 
Features Of Hemolysis HGB <8gm/dl anemia anemia     
DSB 4mg/dl Elevated 
Bilirubin 
Mild jaundice 
LDH >500IU/ml   
Antibody Distribution IgG & C3d 2/2   25/26 5/13  
Elution Glycine Acid 2/2   25/26  7/7 
Antibody specificity Serum & Eluate 1    
 
12 5 
Only Eluate 1 1 2 
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